Human choline acetyltransferase

ABSTRACT

Human choline acetyltransferase polypeptide and DNA (RNA) encoding such polypeptide and a procedure for producing such polypeptide by recombinant techniques is disclosed. Also disclosed are methods for utilizing such polypeptide for the treatment of cognitive and neurological deficiencies or mental disturbances such as degenerative nervous system disorders, for example, Alzheimer&#39;s Disease, ALS and other cholinergic defects, and antagonists for treating Parkinson&#39;s Disease and other disorders relating to an over-expression of acetylcholine. Also disclosed are diagnostic methods for detecting a mutation in the human Choline Acetyltransferase nucleic acid sequence.

CROSS REFERENCE TO RELATED APPLICATIONS

[0001] This application is a divisional of U.S. application Ser. No. 10/177,158, filed Jun. 24, 2002, which is a divisional of Ser. No. 09/939,573, filed Aug. 28, 2001 (now U.S. Pat. No. 6,432,708, issued Aug. 13, 2002), which is a divisional of U.S. application Ser. No. 09/216,993, filed Dec. 15, 1998 (now U.S. Pat. No. 6,319,700, issued on Nov. 20, 2001), which is a divisional of U.S. application Ser. No. 08/464,601, filed Jun. 5, 1995 (now U.S. Pat. No. 6,245,540, issued on Jun. 12, 2001), which is a continuation-in-part of International Application No. PCT/US94/13570, filed Nov. 23, 1994. U.S. application Ser. Nos. 09/939,573, 09/210,993, and 08/464,601 and International Application No. PCT/US94/12570 are hereby incorporated by reference in their entirety.

FIELD OF THE INVENTION

[0002] This invention relates to newly identified polynucleotides, polypeptides encoded by such polynucleotides, the use of such polynucleotides and polypeptides, as well as the production of such polynucleotides and polypeptides. More particularly, the polypeptide of the present invention is choline acetyltransferase, sometimes hereinafter referred to as “hChAT”. The invention also relates to inhibiting the action of such polypeptides.

BACKGROUND OF THE INVENTION

[0003] A human choline acetyltransferase gene has been isolated from the human brain (McGeer P. L. et al., Life Sci., 34:2319-2338 (1984)). Choline acetyltransferase is specifically expressed in cholinergic neurons. Choline acetyltransferase is an enzyme which catalyzes a reaction which yields the neurotransmitter acetylcholine. Although choline acetyltransferase expression has been found in both neurons and certain non-neuronal tissues, such as placenta (Schuberth, J., Biochim. Biophys. Acta, 122:470-481 (1966)) and spermatozoa (Ibanez, C. F. and Persson, H., Eur. J. Neurosci., 3:1309-1315 (1991)), the expression of this enzyme is largely limited to certain neurons.

[0004] The 5′ flanking region of the human choline acetyltransferase gene differs from the rodent gene in that the rodent gene has a “TATAA” box consensus sequence upstream of the transcription start site, but no such element is found in the human gene. The rodent gene also differs in that it contains at least three promoters and the sequence corresponding to only one of the promoters, the M type, is found in the human gene (Hersh, L. B., et al., J. Neurochem., 61:306-314 (1993)).

[0005] The control of motor behavior constitutes one of the most important functions of the central nervous system. Numerous regions of the brain are involved in this process that is integrated ultimately in the motor neurons of the spinal cord, the “final common path” in the control of movement. These neurons, which lie in the ventral horn, exhibit a cholinergic phenotype and, therefore, express choline acetyltransferase. Choline acetyltransferase is a specific marker of the cholinergic system.

BRIEF SUMMARY OF THE INVENTION

[0006] In accordance with one aspect of the present invention, there is provided a novel mature polypeptide which is hChaT, as well as biologically active and diagnostically or therapeutically useful fragments, analogs and derivatives thereof.

[0007] In accordance with another aspect of the present invention, there are provided isolated nucleic acid molecules encoding hChaT, including mRNAs, DNAs, cDNAs, genomic DNA as well as biologically active and diagnostically or therapeutically useful fragments, analogs and derivatives thereof.

[0008] In accordance with yet a further aspect of the present invention, there is provided a process for producing such polypeptide by recombinant techniques which comprises culturing recombinant prokaryotic and/or eukaryotic host cells, containing a hChaT nucleic acid sequence, under conditions promoting expression of said protein and subsequent recovery of said protein.

[0009] In accordance with yet a further aspect of the present invention, there is provided a process for utilizing such polypeptides, or polynucleotide encoding such polypeptide for therapeutic purposes, for example, to treat amyotrophic lateral sclerosis (ALS), Alzheimer's Disease, familial disautonomia, Huntington's Disease, mental retardation, memory loss, myasthenia gravis and other disorders known to involve the cholinergic system or affect its pathways and nerves in the body.

[0010] In accordance with another aspect of the present invention there are provided nucleic acid probes comprising nucleic acid molecules of sufficient length to specifically hybridize to hChaT sequences.

[0011] In accordance with yet a further aspect of the present invention, there are provided antibodies against such polypeptides.

[0012] In accordance with another aspect of the present invention there is provided a method of diagnosing a disease or a susceptibility to a disease, related to a mutation in hChaT nucleic acid sequences and the protein encoded by such nucleic acid sequences, for example, Alzheimer's disease.

[0013] In accordance with yet another aspect of the present invention, there are provided antagonists to such polypeptides, which may be used to inhibit the action of such polypeptides, for example, in the treatment of Parkinson's Disease and accidental overdoses with various pharmaceuticals and contamination by toxins.

[0014] These and other aspects of the present invention should be apparent to those skilled in the art from the teachings herein.

BRIEF DESCRIPTION OF THE DRAWINGS

[0015] The following drawings are illustrative of embodiments of the invention and are not meant to limit the scope of the invention as encompassed by the claims.

[0016] FIGS. 1A-D depict the cDNA sequence (SEQ ID NO:1) and corresponding deduced amino acid sequence (SEQ ID NO:2) of hChat. The hChat polypeptide as shown is the putative mature polypeptide. The standard one-letter abbreviations for amino acids are used.

DETAILED DESCRIPTION

[0017] In accordance with an aspect of the present invention, there is provided an isolated nucleic acid (polynucleotide) which encodes for the mature polypeptide having the deduced amino acid sequence of FIGS. 1A-D (SEQ ID NO:2) or for the mature polypeptide encoded by the cDNA of the clone deposited as ATCC Deposit No. 75856 on Aug. 9, 1994 with the American Type Culture Collection (“ATCC”), 10801 University Boulevard, Manassas, Va. 20110-2209. The strain referred to is being maintained under the terms of the Budapest Treaty, and will be made available to a patent office signatory to the Budapest Treaty.

[0018] A polynucleotide encoding a polypeptide of the present invention may be obtained from fetal liver and fetal lung. The polynucleotide of this invention was discovered in a cDNA library derived from human fetal lung. It contains an open reading frame encoding a protein of 677 amino acid residues. The protein exhibits the highest degree of homology to pig choline acetyltransferase with 43% identity and 64% similarity over a 145 amino acid stretch.

[0019] The polynucleotide of the present invention may be in the form of RNA or in the form of DNA, which DNA includes cDNA, genomic DNA, and synthetic DNA. The DNA may be double-stranded or single-stranded, and if single stranded may be the coding strand or non-coding (anti-sense) strand. The coding sequence which encodes the mature polypeptide may be identical to the coding sequence shown in FIGS. 1A-D or that of the deposited clone or may be a different coding sequence which coding sequence, as a result of the redundancy or degeneracy of the genetic code, encodes the same mature polypeptide as the DNA of FIGS. 1A-D or the deposited cDNA.

[0020] The polynucleotide which encodes for the mature polypeptide of FIGS. 1A-D or for the mature polypeptide encoded by the deposited cDNA may include: only the coding sequence for the mature polypeptide; the coding sequence for the mature polypeptide and additional coding sequence such as a leader or secretory sequence or a proprotein sequence; the coding sequence for the mature polypeptide (and optionally additional coding sequence) and non-coding sequence, such as introns or non-coding sequence 5′ and/or 3′ of the coding sequence for the mature polypeptide.

[0021] Thus, the term “polynucleotide encoding a polypeptide” encompasses a polynucleotide which includes only coding sequence for the polypeptide as well as a polynucleotide which includes additional coding and/or non-coding sequence.

[0022] The present invention further relates to variants of the hereinabove described polynucleotides which encode for fragments, analogs and derivatives of the polypeptide having the deduced amino acid sequence of FIGS. 1A-D (SEQ ID NO:2) or the polypeptide encoded by the cDNA of the deposited clone. The variant of the polynucleotide may be a naturally occurring allelic variant of the polynucleotide or a non-naturally occurring variant of the polynucleotide.

[0023] Thus, the present invention includes polynucleotides encoding the same mature polypeptide as shown in FIGS. 1A-D or the same mature polypeptide encoded by the cDNA of the deposited clone as well as variants of such polynucleotides which variants encode for a fragment, derivative or analog of the polypeptide of FIGS. 1A-D (SEQ ID NO:2) or the polypeptide encoded by the cDNA of the deposited clone. Such nucleotide variants include deletion variants, substitution variants and addition or insertion variants.

[0024] As hereinabove indicated, the polynucleotide may have a coding sequence which is a naturally occurring allelic variant of the coding sequence shown in FIG. 1A-D (SEQ ID NO:1) or of the coding sequence of the deposited clone. As known in the art, an allelic variant is an alternate form of a polynucleotide sequence which may have a substitution, deletion or addition of one or more nucleotides, which does not substantially alter the function of the encoded polypeptide.

[0025] The polynucleotides of the present invention may also have the coding sequence fused in frame to a marker sequence which allows for purification of the polypeptide of the present invention. The marker sequence may be a hexa-histidine tag supplied by a pQE-9 vector to provide for purification of the mature polypeptide fused to the marker in the case of a bacterial host, or, for example, the marker sequence may be a hemagglutinin (HA) tag when a mammalian host, e.g. COS-7 cells, is used. The HA tag corresponds to an epitope derived from the influenza hemagglutinin protein (Wilson, I., et al., Cell, 37:767 (1984)).

[0026] The term “gene” means the segment of DNA involved in producing a polypeptide chain; it includes regions preceding and following the coding region (leader and trailer) as well as intervening sequences (introns) between individual coding segments (exons).

[0027] Fragments of the full length gene of the present invention may be used as a hybridization probe for a cDNA library to isolate the full length cDNA and to isolate other cDNAs which have a high sequence similarity to the gene or similar biological activity. Probes of this type preferably have at least 30 bases and may contain, for example, 50 or more bases. The probe may also be used to identify a cDNA clone corresponding to a full length transcript and a genomic clone or clones that contain the complete gene including regulatory and promotor regions, exons, and introns. An example of a screen comprises isolating the coding region of the gene by using the known DNA sequence to synthesize an oligonucleotide probe. Labeled oligonucleotides having a sequence complementary to that of the gene of the present invention are used to screen a library of human cDNA, genomic DNA or mRNA to determine which members of the library the probe hybridizes to.

[0028] The present invention further relates to polynucleotides which hybridize to the hereinabove-described sequences if there is at least 70%, preferably at least 90%, and more preferably at least 95% identity between the sequences. The present invention particularly relates to polynucleotides which hybridize under stringent conditions to the hereinabove-described polynucleotides. As herein used, the term “stringent conditions” means hybridization will occur only if there is at least 95% and preferably at least 97% identity between the sequences. The polynucleotides which hybridize to the hereinabove described polynucleotides in a preferred embodiment encode polypeptides which either retain substantially the same biological function or activity as the mature polypeptide encoded by the cDNAs of FIGS. 1A-D (SEQ ID NO:1) or the deposited cDNA(s).

[0029] Alternatively, the polynucleotide may have at least 20 bases, preferably 30 bases, and more preferably at least 50 bases which hybridize to a polynucleotide of the present invention and which has an identity thereto, as hereinabove described, and which may or may not retain activity. For example, such polynucleotides may be employed as probes for the polynucleotide of SEQ ID NO:1, for example, for recovery of the polynucleotide or as a diagnostic probe or as a PCR primer.

[0030] Thus, the present invention is directed to polynucleotides having at least a 70% identity, preferably at least 90% and more preferably at least a 95% identity to a polynucleotide which encodes the polypeptide of SEQ ID NO:2 as well as fragments thereof, which fragments have at least 30 bases and preferably at least 50 bases and to polypeptides encoded by such polynucleotides.

[0031] The deposit(s) referred to herein will be maintained under the terms of the Budapest Treaty on the International Recognition of the Deposit of Micro-organisms for purposes of Patent Procedure. These deposits are provided merely as convenience to those of skill in the art and are not an admission that a deposit is required under 35 U.S.C. §112. The sequence of the polynucleotides contained in the deposited materials, as well as the amino acid sequence of the polypeptides encoded thereby, are incorporated herein by reference and are controlling in the event of any conflict with any description of sequences herein. A license may be required to make, use or sell the deposited materials, and no such license is hereby granted.

[0032] The present invention further relates to a polypeptide which has the deduced amino acid sequence of FIGS. 1A-D (SEQ ID NO:2) or which has the amino acid sequence encoded by the deposited cDNA, as well as fragments, analogs and derivatives of such polypeptide.

[0033] The terms “fragment,” “derivative” and “analog” when referring to the polypeptide of FIGS. 1A-D (SEQ ID NO:2) or that encoded by the deposited cDNA, means a polypeptide which retains essentially the same biological function or activity as such polypeptide. Thus, an analog includes a proprotein which can be activated by cleavage of the proprotein portion to produce an active mature polypeptide.

[0034] The polypeptide of the present invention may be a recombinant polypeptide, a natural polypeptide or a synthetic polypeptide, preferably a recombinant polypeptide.

[0035] The fragment, derivative or analog of the polypeptide of FIGS. 1A-D (SEQ ID NO:2) or that encoded by the deposited cDNA may be (i) one in which one or more of the amino acid residues are substituted with a conserved or non-conserved amino acid residue (preferably a conserved amino acid residue) and such substituted amino acid residue may or may not be one encoded by the genetic code, or (ii) one in which one or more of the amino acid residues includes a substituent group, or (iii) one in which the mature polypeptide is fused with another compound, such as a compound to increase the half-life of the polypeptide (for example, polyethylene glycol), or (iv) one in which the additional amino acids are fused to the mature polypeptide, such as a leader or secretory sequence or a sequence which is employed for purification of the mature polypeptide or a proprotein sequence. Such fragments, derivatives and analogs are deemed to be within the scope of those skilled in the art from the teachings herein.

[0036] The polypeptides and polynucleotides of the present invention are preferably provided in an isolated form, and preferably are purified to homogeneity.

[0037] The term “isolated” means that the material is removed from its original environment (e.g., the natural environment if it is naturally occurring). For example, a naturally-occurring polynucleotide or polypeptide present in a living animal is not isolated, but the same polynucleotide or polypeptide, separated from some or all of the coexisting materials in the natural system, is isolated. Such polynucleotides could be part of a vector and/or such polynucleotides or polypeptides could be part of a composition, and still be isolated in that such vector or composition is not part of its natural environment.

[0038] The polypeptides of the present invention include the polypeptide of SEQ ID NO:2 (in particular the mature polypeptide) as well as polypeptides which have at least 70% similarity (preferably at least 70% identity) to the polypeptide of SEQ ID NO:2 and more preferably at least 90% similarity (more preferably at least 90% identity) to the polypeptide of SEQ ID NO:2 and still more preferably at least 95% similarity (still more preferably at least 95% identity) to the polypeptide of SEQ ID NO:2 and also include portions of such polypeptides with such portion of the polypeptide generally containing at least 30 amino acids and more preferably at least 50 amino acids.

[0039] As known in the art “similarity” between two polypeptides is determined by comparing the amino acid sequence and its conserved amino acid substitutes of one polypeptide to the sequence of a second polypeptide.

[0040] Fragments or portions of the polypeptides of the present invention may be employed for producing the corresponding full-length polypeptide by peptide synthesis; therefore, the fragments may be employed as intermediates for producing the full-length polypeptides. Fragments or portions of the polynucleotides of the present invention may be used to synthesize full-length polynucleotides of the present invention.

[0041] The present invention also relates to vectors which include polynucleotides of the present invention, host cells which are genetically engineered with vectors of the invention and the production of polypeptides of the invention by recombinant techniques.

[0042] Host cells are genetically engineered (transduced or transformed or transfected) with the vectors of this invention which may be, for example, a cloning vector or an expression vector. The vector may be, for example, in the form of a plasmid, a viral particle, a phage, etc. The engineered host cells can be cultured in conventional nutrient media modified as appropriate for activating promoters, selecting transformants or amplifying the genes of the present invention. The culture conditions, such as temperature, pH and the like, are those previously used with the host cell selected for expression, and will be apparent to the ordinarily skilled artisan.

[0043] The polynucleotides of the present invention may be employed for producing polypeptides by recombinant techniques. Thus, for example, the polynucleotide may be included in any one of a variety of expression vectors for expressing a polypeptide. Such vectors include chromosomal, nonchromosomal and synthetic DNA sequences, e.g., derivatives of SV40; bacterial plasmids; phage DNA; baculovirus; yeast plasmids; vectors derived from combinations of plasmids and phage DNA, viral DNA such as vaccinia, adenovirus, fowl pox virus, and pseudorabies. However, any other vector may be used as long as it is replicable and viable in the host.

[0044] The appropriate DNA sequence may be inserted into the vector by a variety of procedures. In general, the DNA sequence is inserted into an appropriate restriction endonuclease site(s) by procedures known in the art. Such procedures and others are deemed to be within the scope of those skilled in the art.

[0045] The DNA sequence in the expression vector is operatively linked to an appropriate expression control sequence(s) (promoter) to direct mRNA synthesis. As representative examples of such promoters, there may be mentioned: LTR or SV40 promoter, the E. coli. lac or trp, the phage lambda P_(L) promoter and other promoters known to control expression of genes in prokaryotic or eukaryotic cells or their viruses. The expression vector also contains a ribosome binding site for translation initiation and a transcription terminator. The vector may also include appropriate sequences for amplifying expression.

[0046] In addition, the expression vectors preferably contain one or more selectable marker genes to provide a phenotypic trait for selection of transformed host cells such as dihydrofolate reductase or neomycin resistance for eukaryotic cell culture, or such as tetracycline or ampicillin resistance in E. coli.

[0047] The vector containing the appropriate DNA sequence as hereinabove described, as well as an appropriate promoter or control sequence, may be employed to transform an appropriate host to permit the host to express the protein.

[0048] As representative examples of appropriate hosts, there may be mentioned: bacterial cells, such as E. coli, Streptomyces, Salmonella typhimurium; fungal cells, such as yeast; insect cells such as Drosophila S2 and Spodoptera Sf9; animal cells such as CHO, COS or Bowes melanoma; adenoviruses; plant cells, etc. The selection of an appropriate host is deemed to be within the scope of those skilled in the art from the teachings herein.

[0049] More particularly, the present invention also includes recombinant constructs comprising one or more of the sequences as broadly described above. The constructs comprise a vector, such as a plasmid or viral vector, into which a sequence of the invention has been inserted, in a forward or reverse orientation. In a preferred aspect of this embodiment, the construct further comprises regulatory sequences, including, for example, a promoter, operably linked to the sequence. Large numbers of suitable vectors and promoters are known to those of skill in the art, and are commercially available. The following vectors are provided by way of example; Bacterial: pQE70, pQE60, pQE-9 (Qiagen), pBS, pD10, phagescript, psiX174, pbluescript SK, pbsks, pNH8A, pNH16a, pNH18A, pNH46A (Stratagene); ptrc99a, pKK223-3, pKK233-3, pDR540, pRIT5 (Pharmacia); Eukaryotic: pWLNEO, pSV2CAT, pOG44, pXT1, pSG (Stratagene) pSVK3, pBPV, pMSG, pSVL (Pharmacia). However, any other plasmid or vector may be used as long as they are replicable and viable in the host.

[0050] Promoter regions can be selected from any desired gene using CAT (chloramphenicol transferase) vectors or other vectors with selectable markers. Two appropriate vectors are pKK232-8 and pCM7. Particular named bacterial promoters include lacI, lacZ, T3, T7, gpt, lambda P_(R), P_(L) and trp. Eukaryotic promoters include CMV immediate early, HSV thymidine kinase, early and late SV40, LTRs from retrovirus, and mouse metallothionein-I. Selection of the appropriate vector and promoter is well within the level of ordinary skill in the art.

[0051] In a further embodiment, the present invention relates to host cells containing the above-described constructs. The host cell can be a higher eukaryotic cell, such as a mammalian cell, or a lower eukaryotic cell, such as a yeast cell, or the host cell can be a prokaryotic cell, such as a bacterial cell. Introduction of the construct into the host cell can be effected by calcium phosphate transfection, DEAE-Dextran mediated transfection, or electroporation (Davis, L., Dibner, M., Battey, I., Basic Methods in Molecular Biology, (1986)).

[0052] The constructs in host cells can be used in a conventional manner to produce the gene product encoded by the recombinant sequence. Alternatively, the polypeptides of the invention can be synthetically produced by conventional peptide synthesizers.

[0053] Mature proteins can be expressed in mammalian cells, yeast, bacteria, or other cells under the control of appropriate promoters. Cell-free translation systems can also be employed to produce such proteins using RNAs derived from the DNA constructs of the present invention. Appropriate cloning and expression vectors for use with prokaryotic and eukaryotic hosts are described by Sambrook, et al., Molecular Cloning: A Laboratory Manual, Second Edition, Cold Spring Harbor, N.Y., (1989), the disclosure of which is hereby incorporated by reference.

[0054] Transcription of the DNA encoding the polypeptides of the present invention by higher eukaryotes is increased by inserting an enhancer sequence into the vector. Enhancers are cis-acting elements of DNA, usually about from 10 to 300 bp that act on a promoter to increase its transcription. Examples include the SV40 enhancer on the late side of the replication origin bp 100 to 270, a cytomegalovirus early promoter enhancer, the polyoma enhancer on the late side of the replication origin, and adenovirus enhancers.

[0055] Generally, recombinant expression vectors will include origins of replication and selectable markers permitting transformation of the host cell, e.g., the ampicillin resistance gene of E. coli and S. cerevisiae TRP1 gene, and a promoter derived from a highly-expressed gene to direct transcription of a downstream structural sequence. Such promoters can be derived from operons encoding glycolytic enzymes such as 3-phosphoglycerate kinase (PGK), α-factor, acid phosphatase, or heat shock proteins, among others. The heterologous structural sequence is assembled in appropriate phase with translation initiation and termination sequences. Optionally, the heterologous sequence can encode a fusion protein including an N-terminal identification peptide imparting desired characteristics, e.g., stabilization or simplified purification of expressed recombinant product.

[0056] Useful expression vectors for bacterial use are constructed by inserting a structural DNA sequence encoding a desired protein together with suitable translation initiation and termination signals in operable reading phase with a functional promoter. The vector will comprise one or more phenotypic selectable markers and an origin of replication to ensure maintenance of the vector and to, if desirable, provide amplification within the host. Suitable prokaryotic hosts for transformation include E. coli, Bacillus subtilis, Salmonella typhimurium and various species within the genera Pseudomonas, Streptomyces, and Staphylococcus, although others may also be employed as a matter of choice.

[0057] As a representative but nonlimiting example, useful expression vectors for bacterial use can comprise a selectable marker and bacterial origin of replication derived from commercially available plasmids comprising genetic elements of the well known cloning vector pBR322 (ATCC 37017). Such commercial vectors include, for example, pKK223-3 (Pharmacia Fine Chemicals, Uppsala, Sweden) and GEM1 (Promega Biotec, Madison, Wis., USA). These pBR322 “backbone” sections are combined with an appropriate promoter and the structural sequence to be expressed.

[0058] Following transformation of a suitable host strain and growth of the host strain to an appropriate cell density, the selected promoter is induced by appropriate means (e.g., temperature shift or chemical induction) and cells are cultured for an additional period.

[0059] Cells are typically harvested by centrifugation, disrupted by physical or chemical means, and the resulting crude extract retained for further purification.

[0060] Microbial cells employed in expression of proteins can be disrupted by any convenient method, including freeze-thaw cycling, sonication, mechanical disruption, or use of cell lysing agents, such methods are well known to those skilled in the art.

[0061] Various mammalian cell culture systems can also be employed to express recombinant protein. Examples of mammalian expression systems include the COS-7 lines of monkey kidney fibroblasts, described by Gluzman, Cell, 23:175 (1981), and other cell lines capable of expressing a compatible vector, for example, the C127, 3T3, CHO, HeLa and BHK cell lines. Mammalian expression vectors will comprise an origin of replication, a suitable promoter and enhancer, and also any necessary ribosome binding sites, polyadenylation site, splice donor and acceptor sites, transcriptional termination sequences, and 5′ flanking nontranscribed sequences. DNA sequences derived from the SV40 splice, and polyadenylation sites may be used to provide the required nontranscribed genetic elements.

[0062] The polypeptide can be recovered and purified from recombinant cell cultures by methods including ammonium sulfate or ethanol precipitation, acid extraction, anion or cation exchange chromatography, phosphocellulose chromatography, hydrophobic interaction chromatography, affinity chromatography, hydroxylapatite chromatography and lectin chromatography. Protein refolding steps can be used, as necessary, in completing configuration of the mature protein. Finally, high performance liquid chromatography (HPLC) can be employed for final purification steps.

[0063] The polypeptides of the present invention may be a naturally purified product, or a product of chemical synthetic procedures, or produced by recombinant techniques from a prokaryotic or eukaryotic host (for example, by bacterial, yeast, higher plant, insect and mammalian cells in culture). Depending upon the host employed in a recombinant production procedure, the polypeptides of the present invention may be glycosylated or may be non-glycosylated. Polypeptides of the invention may also include an initial methionine amino acid residue.

[0064] The hChat polypeptides of the present invention catalyze the transfer of the acyl-group to choline to yield acetylcholine. A deficiency of the neurotransmitter acetylcholine leads to cognitive and/or neurological deficiencies and/or mood or mental disturbances, such as suffering from degenerative nervous system disorders.

[0065] Accordingly, the hChat polypeptides of the present invention may be employed to treat amyotrophic lateral sclerosis, Alzheimer's Disease, senile-dementia, multi-infarct dementia, familial disautonomia, Huntington's Disease, mental retardation, memory loss and myasthenia gravis.

[0066] The hChat polypeptides may also be employed to treat disorders known to involve the cholinergic system or affect its pathways and nerves in the body. Examples of such disorders include gut and GI disorders, cord disorders, including movement, continence and sensation, stem disorders, including sleep, blood pressure, respiration, and balance, hypothalamus disorders, including temperature, respiration, and endocrine function, and limbic system disorders, including schizophrenia, memory disorders, and dementia.

[0067] In accordance with yet a further aspect of the present invention, there is provided a process for utilizing such polypeptides, or polynucleotides encoding such polypeptides, for in vitro purposes related to scientific research, synthesis of DNA and manufacture of DNA vectors. For example, the polynucleotides and polypeptides of the present invention may be employed as research reagents and materials for discovery of treatments and diagnostics to human disease.

[0068] This invention provides a method for identification of the receptor for hChat. The gene encoding the receptor can be identified by numerous methods known to those of skill in the art, for example, ligand panning and FACS sorting (Coligan, et al., Current Protocols in Immun., 1(2), Chapter 5, (1991)). Preferably, expression cloning is employed wherein polyadenylated RNA is prepared from a cell responsive to hChat, and a cDNA library created from this RNA is divided into pools and used to transfect COS cells or other cells that are not responsive to hChat. Transfected cells which are grown on glass slides are exposed to labeled hChat. hChat can be labeled by a variety of means including iodination or inclusion of a recognition site for a site-specific protein kinase. Following fixation and incubation, the slides are subjected to autoradiographic analysis. Positive pools are identified and sub-pools are prepared and retransfected using an iterative sub-pooling and rescreening process, eventually yielding a single clone that encodes the putative receptor.

[0069] As an alternative approach for receptor identification, labeled hChat can be photoaffinity linked with cell membrane or extract preparations that express the receptor molecule. Cross-linked material is resolved by SDS-PAGE and exposed to X-ray film. The labeled complex containing the hChat-receptor can be excised, resolved into peptide fragments, and subjected to protein microsequencing. The amino acid sequence obtained from microsequencing would be used to design a set of degenerate oligonucleotide probes to screen a cDNA library to identify the gene encoding the putative receptor.

[0070] This invention also provides a method of screening compounds to identify those which specifically interact with, and enhance or block, the synthesis of acetylcholine by choline acetyltransferase. An example of such a method includes incubating acetyl-CoA, choline, hChat and the potential agonist or antagonist under appropriate conditions such that hChat would normally catalyzes the transfer of the acyl-group to choline to yield acetylcholine. Results can be measured as pmol of acetylcholine formed per minute and per mg of protein. Control reactions could be performed in the absence of the agonist or antagonist such that an increased or decreased production of acetylcholine necessitates the finding of the agonist or antagonist as effective.

[0071] A potential hChaT antagonist is an antibody, or in some cases, an oligonucleotide, which binds to hChat and blocks its interaction with acetyl-CoA. Potential antagonists may also be proteins which are closely related to hChat but impart no biological functions such that the synthesis of acetylcholine is prevented, e.g., fragments of hChat.

[0072] Potential hChaT antagonists also include antisense constructs prepared using antisense technology. Antisense technology can be used to control gene expression through triple-helix formation or antisense DNA or RNA, both of which methods are based on binding of a polynucleotide to DNA or RNA. For example, the 5′ coding portion of the polynucleotide sequence, which encodes for the mature polypeptides of the present invention, is used to design an antisense RNA oligonucleotide of from about 10 to 40 base pairs in length. A DNA oligonucleotide is designed to be complementary to a region of the gene involved in transcription (triple helix—see Lee et al., Nucl. Acids Res., 6:3073 (1979); Cooney et al, Science, 241:456 (1988); and Dervan et al., Science, 251: 1360 (1991)), thereby preventing transcription and the production of hChat. The antisense RNA oligonucleotide hybridizes to the mRNA in vivo and blocks translation of the mRNA molecule into the hChat polypeptide (antisense—Okano, J. Neurochem., 56:560 (1991); Oligodeoxynucleotides as Antisense Inhibitors of Gene Expression, CRC Press, Boca Raton, Fla. (1988)). The oligonucleotides described above can also be delivered to cells such that the antisense RNA or DNA may be expressed in vivo to inhibit production of hChat.

[0073] A potential antagonist includes a small molecule which binds to and occupies the catalytic site of the hChat polypeptide thereby making the catalytic site inaccessible to acetyl-CoA such that synthesis of acetylcholine is prevented. Examples of small molecules include, but are not limited to, small peptides or peptide-like molecules.

[0074] The antagonists may be employed to treat Parkinson's Disease, which produces a relative excess of acetylcholine because of the loss of dopamine. Similarly, accidental overdoses with various pharmaceuticals and contamination by toxins can also produce relative over-activity of the cholinergic system and may be treated with the antagonists of the present invention.

[0075] The antagonists may be employed in a composition with a pharmaceutically acceptable carrier, e.g., as hereinafter described.

[0076] The hChat polypeptides and agonists and antagonists may be employed in combination with a suitable pharmaceutical carrier. Such compositions comprise a therapeutically effective amount of the polypeptide or compound, and a pharmaceutically acceptable carrier or excipient. Such a carrier includes but is not limited to saline, buffered saline, dextrose, water, glycerol, ethanol, and combinations thereof. The formulation should suit the mode of administration.

[0077] The invention also provides a pharmaceutical pack or kit comprising one or more containers filled with one or more of the ingredients of the pharmaceutical compositions of the invention. Associated with such container(s) can be a notice in the form prescribed by a governmental agency regulating the manufacture, use or sale of pharmaceuticals or biological products, which notice reflects approval by the agency of manufacture, use or sale for human administration. In addition, the pharmaceutical compositions may be employed in conjunction with other therapeutic compounds.

[0078] These pharmaceutical compositions are administered in a convenient manner such as by the intravenous, intracerebral, intraperitoneal, intramuscular, subcutaneous, intranasal or intradermal routes. The pharmaceutical compositions are administered in an amount which is effective for treating and/or prophylaxis of the specific indication. In general, the pharmaceutical compositions will be administered in an amount of at least about 10 μg/kg body weight and in most cases they will be administered in an amount not in excess of about 8 mg/Kg body weight per day. In most cases, the dosage is from about 10 μg/kg to about 1 mg/kg body weight daily, taking into account the routes of administration, symptoms, etc.

[0079] The hChat polypeptides, agonists and antagonists which are polypeptides may also be employed in accordance with the present invention by expression of such polypeptides in vivo, which is often referred to as “gene therapy.”

[0080] Thus, for example, cells from a patient may be engineered with a polynucleotide (DNA or RNA) encoding a polypeptide ex vivo, with the engineered cells then being provided to a patient to be treated with the polypeptide. Such methods are well-known in the art. For example, cells may be engineered by procedures known in the art by use of a retroviral particle containing RNA encoding a polypeptide of the present invention.

[0081] Similarly, cells may be engineered in vivo for expression of a polypeptide in vivo by, for example, procedures known in the art. As known in the art, a producer cell for producing a retroviral particle containing RNA encoding the polypeptide of the present invention may be administered to a patient for engineering cells in vivo and expression of the polypeptide in vivo. These and other methods for administering a polypeptide of the present invention by such method should be apparent to those skilled in the art from the teachings of the present invention. For example, the expression vehicle for engineering cells may be other than a retrovirus, for example, an adenovirus which may be used to engineer cells in vivo after combination with a suitable delivery vehicle.

[0082] Retroviruses from which the retroviral plasmid vectors hereinabove mentioned may be derived include, but are not limited to, Moloney Murine Leukemia Virus, spleen necrosis virus, retroviruses such as Rous Sarcoma Virus, Harvey Sarcoma Virus, avian leukosis virus, gibbon ape leukemia virus, human immunodeficiency virus, adenovirus, Myeloproliferative Sarcoma Virus, and mammary tumor virus. In one embodiment, the retroviral plasmid vector is derived from Moloney Murine Leukemia Virus.

[0083] The vector includes one or more promoters. Suitable promoters which may be employed include, but are not limited to, the retroviral LTR; the SV40 promoter; and the human cytomegalovirus (CMV) promoter described in Miller, et al., Biotechniques, Vol. 7, No. 9, 980-990 (1989), or any other promoter (e.g., cellular promoters such as eukaryotic cellular promoters including, but not limited to, the histone, pol III, and β-actin promoters). Other viral promoters which may be employed include, but are not limited to, adenovirus promoters, thymidine kinase (TK) promoters, and B19 parvovirus promoters. The selection of a suitable promoter will be apparent to those skilled in the art from the teachings contained herein.

[0084] The nucleic acid sequence encoding the polypeptide of the present invention is under the control of a suitable promoter. Suitable promoters which may be employed include, but are not limited to, adenoviral promoters, such as the adenoviral major late promoter; or hetorologous promoters, such as the cytomegalovirus (CMV) promoter; the respiratory syncytial virus (RSV) promoter; inducible promoters, such as the MMT promoter, the metallothionein promoter; heat shock promoters; the albumin promoter; the ApoAI promoter; human globin promoters; viral thymidine kinase promoters, such as the Herpes Simplex thymidine kinase promoter; retroviral LTRs (including the modified retroviral LTRs hereinabove described); the β-actin promoter; and human growth hormone promoters. The promoter also may be the native promoter which controls the gene encoding the polypeptide.

[0085] The retroviral plasmid vector is employed to transduce packaging cell lines to form producer cell lines. Examples of packaging cells which may be transfected include, but are not limited to, the PE501, PA317, ψ-2, ψ-AM, PA12, T19-14X, VT-19-17-H2, ψCRE, ψCRIP, GP+E-86, GP+envAm12, and DAN cell lines as described in Miller, Human Gene Therapy, Vol. 1, pgs. 5-14 (1990), which is incorporated herein by reference in its entirety. The vector may transduce the packaging cells through any means known in the art. Such means include, but are not limited to, electroporation, the use of liposomes, and CaPO₄ precipitation. In one alternative, the retroviral plasmid vector may be encapsulated into a liposome, or coupled to a lipid, and then administered to a host.

[0086] The producer cell line generates infectious retroviral vector particles which include the nucleic acid sequence(s) encoding the polypeptides. Such retroviral vector particles then may be employed, to transduce eukaryotic cells, either in vitro or in vivo. The transduced eukaryotic cells will express the nucleic acid sequence(s) encoding the polypeptide. Eukaryotic cells which may be transduced include, but are not limited to, embryonic stem cells, embryonic carcinoma cells, as well as hematopoietic stem cells, hepatocytes, fibroblasts, myoblasts, keratinocytes, endothelial cells, and bronchial epithelial cells.

[0087] This invention is also related to the use of the hChaT gene as part of a diagnostic assay for detecting diseases or susceptibility to diseases related to the presence of mutated hChaT. Such diseases are related to an acetylcholine deficiency, for example, neurological disorders. Individuals carrying mutations in the hChaT gene may be detected at the DNA level by a variety of techniques. Nucleic acids for diagnosis may be obtained from a patient's cells, such as from blood, tissue biopsy and autopsy material. The genomic DNA may be used directly for detection or may be amplified enzymatically by using PCR (Saiki et al., Nature, 324:163-166 (1986)) prior to analysis. RNA or cDNA may also be used for the same purpose. As an example, PCR primers complementary to the nucleic acid encoding hChaT can be used to identify and analyze hChaT mutations. For example, deletions and insertions can be detected by a change in size of the amplified product in comparison to the normal genotype. Point mutations can be identified by hybridizing amplified DNA to radiolabeled hChaT RNA or alternatively, radiolabeled hChaT antisense DNA sequences. Perfectly matched sequences can be distinguished from mismatched duplexes by RNase A digestion or by differences in melting temperatures.

[0088] Genetic testing based on DNA sequence differences may be achieved by detection of alteration in electrophoretic mobility of DNA fragments in gels with or without denaturing agents. Small sequence deletions and insertions can be visualized by high resolution gel electrophoresis. DNA fragments of different sequences may be distinguished on denaturing formamide gradient gels in which the mobilities of different DNA fragments are retarded in the gel at different positions according to their specific melting or partial melting temperatures (see, e.g., Myers et al., Science, 230:1242 (1985)).

[0089] Sequence changes at specific locations may also be revealed by nuclease protection assays, such as RNase and S1 protection or the chemical cleavage method (e.g., Cotton et al., PNAS, USA, 85:4397-4401 (1985)).

[0090] Thus, the detection of a specific DNA sequence may be achieved by methods such as hybridization, RNase protection, chemical cleavage, direct DNA sequencing or the use of restriction enzymes, (e.g., Restriction Fragment Length Polymorphisms (RFLP)) and Southern blotting of genomic DNA.

[0091] In addition to more conventional gel-electrophoresis and DNA sequencing, mutations can also be detected by in situ analysis.

[0092] The present invention also relates to a diagnostic assay for detecting altered levels of hChat protein in various tissues since an over-expression of the proteins compared to normal control tissue samples may detect the presence of a neurological disease or susceptibility to a neurological disease. Assays used to detect levels of hChat protein in a sample derived from a host are well-known to those of skill in the art and include radioimmunoassays, competitive-binding assays, Western Blot analysis, ELISA assays and “sandwich” assay. An ELISA assay (Coligan, et al., Current Protocols in Immunology, 1(2), Chapter 6, (1991)) initially comprises preparing an antibody specific to the hChat antigen, preferably a monoclonal antibody. In addition a reporter antibody is prepared against the monoclonal antibody. To the reporter antibody is attached a detectable reagent such as radioactivity, fluorescence or, in this example, a horseradish peroxidase enzyme. A sample is removed from a host and incubated on a solid support, e.g. a polystyrene dish, that binds the proteins in the sample. Any free protein binding sites on the dish are then covered by incubating with a non-specific protein like BSA. Next, the monoclonal antibody is incubated in the dish during which time the monoclonal antibodies attach to any hChat proteins attached to the polystyrene dish. All unbound monoclonal antibody is washed out with buffer. The reporter antibody linked to horseradish peroxidase is now placed in the dish resulting in binding of the reporter antibody to any monoclonal antibody bound to hChat. Unattached reporter antibody is then washed out. Peroxidase substrates are then added to the dish and the amount of color developed in a given time period is a measurement of the amount of hChat protein present in a given volume of patient sample when compared against a standard curve.

[0093] A competition assay may be employed wherein antibodies specific to hChat are attached to a solid support and labeled hChat and a sample derived from the host are passed over the solid support and the amount of label detected, for example by liquid scintillation chromatography, can be correlated to a quantity of hChat in the sample.

[0094] A “sandwich” assay is similar to an ELISA assay. In a “sandwich” assay hChat is passed over a solid support and binds to antibody attached to a solid support. A second antibody is then bound to the hChat. A third antibody which is labeled and specific to the second antibody is then passed over the solid support and binds to the second antibody and an amount can then be quantitated.

[0095] The sequences of the present invention are also valuable for chromosome identification. The sequence is specifically targeted to and can hybridize with a particular location on an individual human chromosome. Moreover, there is a current need for identifying particular sites on the chromosome. Few chromosome marking reagents based on actual sequence data (repeat polymorphisms) are presently available for marking chromosomal location. The mapping of DNAs to chromosomes according to the present invention is an important first step in correlating those sequences with genes associated with disease.

[0096] Briefly, sequences can be mapped to chromosomes by preparing PCR primers (preferably 15-25 bp) from the cDNA. Computer analysis of the 3′ untranslated region is used to rapidly select primers that do not span more than one exon in the genomic DNA, thus complicating the amplification process. These primers are then used for PCR screening of somatic cell hybrids containing individual human chromosomes. Only those hybrids containing the human gene corresponding to the primer will yield an amplified fragment.

[0097] PCR mapping of somatic cell hybrids is a rapid procedure for assigning a particular DNA to a particular chromosome. Using the present invention with the same oligonucleotide primers, sublocalization can be achieved with panels of fragments from specific chromosomes or pools of large genomic clones in an analogous manner. Other mapping strategies that can similarly be used to map to its chromosome include in situ hybridization, prescreening with labeled flow-sorted chromosomes and preselection by hybridization to construct chromosome specific-cDNA libraries.

[0098] Fluorescence in situ hybridization (FISH) of a cDNA clone to a metaphase chromosomal spread can be used to provide a precise chromosomal location in one step. This technique can be used with cDNA as short as 50 or 60 bases. For a review of this technique, see Verma et al., Human Chromosomes: a Manual of Basic Techniques, Pergamon Press, New York (1988).

[0099] Once a sequence has been mapped to a precise chromosomal location, the physical position of the sequence on the chromosome can be correlated with genetic map data. Such data are found, for example, in V. McKusick, Mendelian Inheritance in Man (available on line through Johns Hopkins University Welch Medical Library). The relationship between genes and diseases that have been mapped to the same chromosomal region are then identified through linkage analysis (coinheritance of physically adjacent genes).

[0100] Next, it is necessary to determine the differences in the cDNA or genomic sequence between affected and unaffected individuals. If a mutation is observed in some or all of the affected individuals but not in any normal individuals, then the mutation is likely to be the causative agent of the disease.

[0101] With current resolution of physical mapping and genetic mapping techniques, a cDNA precisely localized to a chromosomal region associated with the disease could be one of between 50 and 500 potential causative genes. (This assumes 1 megabase mapping resolution and one gene per 20 kb).

[0102] The polypeptides, their fragments or other derivatives, or analogs thereof, or cells expressing them can be used as an immunogen to produce antibodies thereto. These antibodies can be, for example, polyclonal or monoclonal antibodies. The present invention also includes chimeric, single chain, and humanized antibodies, as well as Fab fragments, or the product of an Fab expression library. Various procedures known in the art may be used for the production of such antibodies and fragments.

[0103] Antibodies generated against the polypeptides corresponding to a sequence of the present invention can be obtained by direct injection of the polypeptides into an animal or by administering the polypeptides to an animal, preferably a nonhuman. The antibody so obtained will then bind the polypeptides itself. In this manner, even a sequence encoding only a fragment of the polypeptides can be used to generate antibodies binding the whole native polypeptides. Such antibodies can then be used to isolate the polypeptide from tissue expressing that polypeptide.

[0104] For preparation of monoclonal antibodies, any technique which provides antibodies produced by continuous cell line cultures can be used. Examples include the hybridoma technique (Kohler and Milstein, 1975, Nature, 256:495-497), the trioma technique, the human B-cell hybridoma technique (Kozbor et al., 1983, Immunology Today 4:72), and the EBV-hybridoma technique to produce human monoclonal antibodies (Cole, et al., 1985, in Monoclonal Antibodies and Cancer Therapy, Alan R. Liss, Inc., pp. 77-96).

[0105] Techniques described for the production of single chain antibodies (U.S. Pat. No. 4,946,778) can be adapted to produce single chain antibodies to immunogenic polypeptide products of this invention. Also, transgenic mice may be used to express humanized antibodies to immunogenic polypeptide products of this invention.

[0106] The present invention will be further described with reference to the following examples; however, it is to be understood that the present invention is not limited to such examples. All parts or amounts, unless otherwise specified, are by weight.

[0107] In order to facilitate understanding of the following examples certain frequently occurring methods and/or terms will be described.

[0108] “Plasmids” are designated by a lower case p preceded and/or followed by capital letters and/or numbers. The starting plasmids herein are either commercially available, publicly available on an unrestricted basis, or can be constructed from available plasmids in accord with published procedures. In addition, equivalent plasmids to those described are known in the art and will be apparent to the ordinarily skilled artisan.

[0109] “Digestion” of DNA refers to catalytic cleavage of the DNA with a restriction enzyme that acts only at certain sequences in the DNA. The various restriction enzymes used herein are commercially available and their reaction conditions, cofactors and other requirements are used as would be known to the ordinarily skilled artisan. For analytical purposes, typically 1 μg of plasmid or DNA fragment is used with about 2 units of enzyme in about 20 μl of buffer solution. For the purpose of isolating DNA fragments for plasmid construction, typically 5 to 50 μg of DNA are digested with 20 to 250 units of enzyme in a larger volume. Appropriate buffers and substrate amounts for particular restriction enzymes are specified by the manufacturer. Incubation times of about 1 hour at 37° C. are ordinarily used, but may vary in accordance with the supplier's instructions. After digestion the reaction is electrophoresed directly on a polyacrylamide gel to isolate the desired fragment.

[0110] Size separation of the cleaved fragments is performed using 8 percent polyacrylamide gel described by Goeddel, D. et al., Nucleic Acids Res., 8:4057 (1980).

[0111] “Oligonucleotides” refers to either a single stranded polydeoxynucleotide or two complementary polydeoxynucleotide strands which may be chemically synthesized. Such synthetic oligonucleotides have no 5′ phosphate and thus will not ligate to another oligonucleotide without adding a phosphate with an ATP in the presence of a kinase. A synthetic oligonucleotide will ligate to a fragment that has not been dephosphorylated.

[0112] “Ligation” refers to the process of forming phosphodiester bonds between two double stranded nucleic acid fragments (Maniatis, T., et al., Id., p. 146). Unless otherwise provided, ligation may be accomplished using known buffers and conditions with 10 units to T4 DNA ligase (“ligase”) per 0.5 μg of approximately equimolar amounts of the DNA fragments to be ligated.

[0113] Unless otherwise stated, transformation was performed as described in the method of Graham, F. and Van der Eb, A., Virology, 52:456-457 (1973).

EXAMPLE 1 Bacterial Expression and Purification of hChat

[0114] The DNA sequence encoding hChat, ATCC # 75856, is initially amplified using PCR oligonucleotide primers corresponding to the 5′ and sequences of the processed hChat protein (minus the signal peptide sequence) and the vector sequences 3′ to the hChat gene. Additional nucleotides corresponding to hChat are added to the 5′ and 3′ sequences respectively. The 5′ oligonucleotide primer has the sequence 5′ CGCGAGATCCACCATGAAGGCTTCCAGCCGCTTC 3′ (SEQ ID NO:3) contains a BamHI restriction enzyme site (underlined) followed by 21 nucleotides of hChat coding sequence starting from the presumed terminal amino acid of the processed protein codon. The 3′ sequence 5′ CGCGTCTAGAAGGGTACAGATGGTGGCC 3′ (SEQ ID NO:4) contains complementary sequences to an XbaI site (underlined) and is followed by 18 nucleotides of hChat noncoding sequence located 3′ to the hChat DNA insert. The restriction enzyme sites correspond to the restriction enzyme sites on the bacterial expression vector pQE-9 (Qiagen, Inc. Chatsworth, Calif.). pQE-9 encodes antibiotic resistance (Amp^(r)), a bacterial origin of replication (ori), an IPTG-regulatable promoter operator (P/O), a ribosome binding site (RBS), a 6-His tag and restriction enzyme sites. pQE-9 is then digested with BamHI and XbaI. The amplified sequences are ligated into pQE-9 and are inserted in frame with the sequence encoding for the histidine tag and the RBS. The ligation mixture is then used to transform E. coli strain m15/REP4 available from Qiagen by the procedure described in Sambrook, J. et al., Molecular Cloning: A Laboratory Manual, Cold Spring Laboratory Press, (1989). M15/rep4 contains multiple copies of the plasmid pREP4, which expresses the lacI repressor and also confers kanamycin resistance (Kan^(r)). Transformants are identified by their ability to grow on LB plates and ampicillin/kanamycin resistant colonies are selected. Plasmid DNA is isolated and confirmed by restriction analysis. Clones containing the desired constructs are grown overnight (O/N) in liquid culture in LB media supplemented with both Amp (100 μg/ml) and Kan (25 ug/ml). The O/N culture is used to inoculate a large culture at a ratio of 1:100 to 1:250. The cells are grown to an optical density 600 (O.D.⁶⁰⁰) of between 0.4 and 0.6. IPTG (“Isopropyl-B-D-thiogalacto pyranoside”) is then added to a final concentration of 1 mM. IPTG induces by inactivating the lacI repressor, clearing the P/O leading to increased gene expression. Cells are grown an extra 3 to 4 hours. Cells are then harvested by centrifugation. The cell pellet is solubilized in the chaotropic agent 6 Molar Guanidine HCl. After clarification, solubilized hChat is purified from this solution by chromatography on a Nickel-Chelate column under conditions that allow for tight binding by proteins containing the 6-His tag (Hochuli, E. et al., J. Chromatography 411:177-184 (1984)). hChat is eluted from the column in 6 molar guanidine HCl pH 5.0 and for the purpose of renaturation adjusted to 3 molar guanidine HCl, 100 mM sodium phosphate, 10 mmolar glutathione (reduced) and 2 mmolar glutathione (oxidized). After incubation in this solution for 12 hours the protein is dialyzed to 10 mmolar sodium phosphate.

EXAMPLE 2 Cloning and Expression of hChat Using the Baculovirus Expression System

[0115] The DNA sequence encoding the full length hChat protein, ATCC # 75856, is amplified using PCR oligonucleotide primers corresponding to the 5′ and 3′ sequences of the gene:

[0116] The 5′ primer has the sequence 5′ CGCGGGATCCACCATGAAGGCTTCCAGCCGCTTC 3′ (SEQ ID NO:5) and contains a Bam HI restriction enzyme site (in bold) followed by 3 non-specific nucleotides and 21 nucleotides encoding hChat which resembles an efficient signal for the initiation of translation in eukaryotic cells (J. Mol. Biol. 1987, 196, 947-950, Kozak, M.).

[0117] The 3′ primer has the sequence 5′ CGCGGGTACCAGGTACAGATGGTGGCC 3′ (SEQ ID NO:6) and contains the cleavage site for the restriction endonuclease Asp718 (in bold) followed by 16 nucleotides complementary to the coding region of hChat. The amplified sequences are isolated from a 1% agarose gel using a commercially available kit (“Geneclean,” BIO 101 Inc., La Jolla, Calif.). The fragment is then digested with the endonucleases Bam H1 and Asp718 and then purified as described above. This fragment is designated F2.

[0118] The vector pA35 (modification of pVL941 vector, discussed below) is used for the expression of the hChat protein using the baculovirus expression system (for review see: Summers, M. D. and Smith, G. E. 1987, A manual of methods for baculovirus vectors and insect cell culture procedures, Texas Agricultural Experimental Station Bulletin No. 1555). This expression vector contains the strong polyhedrin promoter of the Autographa californica nuclear polyhedrosis virus (AcMNPV) followed by the recognition sites for the restriction endonucleases Bam H1 and Asp718. The polyadenylation site of the simian virus (SV)40 is used for efficient polyadenylation. For an easy selection of recombinant viruses the beta-galactosidase gene from E.coli is inserted in the same orientation as the polyhedrin promoter followed by the polyadenylation signal of the polyhedrin gene. The polyhedrin sequences are flanked at both sides by viral sequences for the cell-mediated homologous recombination of cotransfected wild-type viral DNA. Many other baculovirus vectors could be used in place of pRG1 such as pRG1, pAc373, pVL941 and pAcIM1 (Luckow, V. A. and Summers, M. D., Virology, 170:31-39).

[0119] The plasmid is digested with the restriction enzymes Bam H1 and Asp718 and then dephosphorylated using calf intestinal phosphatase by procedures known in the art. The DNA is then isolated from a 1% agarose gel. This vector DNA is designated V2.

[0120] Fragment F2 and the dephosphorylated plasmid V2 are ligated with T4 DNA ligase. E.coli HB101 cells are then transformed and bacteria identified that contained the plasmid (pBac hChat) with the hChat gene using the enzymes Bam HI and Asp718. The sequence of the cloned fragment is confirmed by DNA sequencing.

[0121] 5 μg of the plasmid pBac hChat are cotransfected with 1.0 μg of a commercially available linearized baculovirus (“BaculoGold™ baculovirus DNA”, Pharmingen, San Diego, Calif.) using the lipofection method (Felgner et al. Proc. Natl. Acad. Sci. USA, 84:7413-7417 (1987)).

[0122] 1 μg of BaculoGold™ virus DNA and 5 μg of the plasmid pBac hChat are mixed in a sterile well of a microtiter plate containing 50 μl of serum free Grace's medium (Life Technologies Inc., Gaithersburg, Md.). Afterwards 10 μl Lipofectin plus 90 μl Grace's medium are added, mixed and incubated for 15 minutes at room temperature. Then the transfection mixture is added drop-wise to the Sf9 insect cells (ATCC CRL 1711) seeded in a 35 mm tissue culture plate with 1 ml Grace' medium without serum. The plate is rocked back and forth to mix the newly added solution. The plate is then incubated for 5 hours at 27° C. After 5 hours the transfection solution is removed from the plate and 1 ml of Grace's insect medium supplemented with 10% fetal calf serum is added. The plate is put back into an incubator and cultivation continued at 27° C. for four days.

[0123] After four days the supernatant is collected and a plaque assay performed similar as described by Summers and Smith (supra). As a modification an agarose gel with “Blue Gal” (Life Technologies Inc., Gaithersburg) is used which allows an easy isolation of blue stained plaques. (A detailed description of a “plaque assay” can also be found in the user's guide for insect cell culture and baculovirology distributed by Life Technologies Inc., Gaithersburg, page 9-10).

[0124] Four days after the serial dilution of the viruses is added to the cells, blue stained plaques are picked with the tip of an Eppendorf pipette. The agar containing the recombinant viruses is then resuspended in an Eppendorf tube containing 200 μl of Grace's medium. The agar is removed by a brief centrifugation and the supernatant containing the recombinant baculoviruses is used to infect Sf9 cells seeded in 35 mm dishes. Four days later the supernatants of these culture dishes are harvested and then stored at 4° C.

[0125] Sf9 cells are grown in Grace's medium supplemented with 10% heat-inactivated FBS. The cells are infected with the recombinant baculovirus V-hChat at a multiplicity of infection (MOI) of 2. Six hours later the medium is removed and replaced with SF900 II medium minus methionine and cysteine (Life Technologies Inc., Gaithersburg). 42 hours later 5 μCi of ³⁵S-methionine and 5 μCi ³⁵S cysteine (Amersham) are added. The cells are further incubated for 16 hours before they are harvested by centrifugation and the labeled proteins visualized by SDS-PAGE and autoradiography.

EXAMPLE 3 Expression of Recombinant hChat in COS Cells

[0126] The expression of plasmid, hChat HA is derived from a vector pcDNAI/Amp (Invitrogen) containing: 1) SV40 origin of replication, 2) ampicillin resistance gene, 3) E.coli replication origin, 4) CMV promoter followed by a polylinker region, a SV40 intron and polyadenylation site. A DNA fragment encoding the entire hChat precursor and a HA tag fused in frame to its 3′ end is cloned into the polylinker region of the vector, therefore, the recombinant protein expression is directed under the CMV promoter. The HA tag correspond to an epitope derived from the influenza hemagglutinin protein as previously described (I. Wilson, H. Niman, R. Heighten, A Cherenson, M. Connolly, and R. Lerner, 1984, Cell 37, 767). The infusion of HA tag to our target protein allows easy detection of the recombinant protein with an antibody that recognizes the HA epitope.

[0127] The plasmid construction strategy is described as follows:

[0128] The DNA sequence encoding hChat, ATCC# 75856, is constructed by PCR on the original EST cloned using two primers: the 5′ primer 5′ CGCGGGATCCACCATGAAGGCTTCCAGCCGCTTC 3′ (SEQ ID NO:7) contains a Bam H1 site (bold) followed by 21 nucleotides of hChat coding sequence starting from the initiation codon; the 3′ sequence 5′ CGCGTCTAGATCAAGCGTAGTCTGGGACGTCGTATGGGTAGCCTCTGCACTCAGCCCC 3′ (SEQ ID NO:8) contains complementary sequences to an Xba I site (bold), translation stop codon, HA tag and the last 18 nucleotides of the hChat coding sequence (not including the stop codon). Therefore, the PCR product contains a Bam HI site, hChat coding sequence followed by HA tag fused in frame, a translation termination stop codon next to the HA tag, and an Xba I site. The PCR amplified DNA fragment and the vector, pcDNAI/Amp, are digested with Bam H1 and Xba I restriction enzyme and ligated. The ligation mixture is transformed into E. coli strain SURE (available from Stratagene Cloning Systems, 11099 North Torrey Pines Road, La Jolla, Calif. 92037) the transformed culture is plated on ampicillin media plates and resistant colonies are selected. Plasmid DNA is isolated from transformants and examined by restriction analysis for the presence of the correct fragment. For expression of the recombinant hChat, COS cells are transfected with the expression vector by DEAE-DEXTRAN method (J. Sambrook, E. Fritsch, T. Maniatis, Molecular Cloning: A Laboratory Manual, Cold Spring Laboratory Press, (1989)). The expression of the hChat HA protein is detected by radiolabelling and immunoprecipitation method (E. Harlow, D. Lane, Antibodies: A Laboratory Manual, Cold Spring Harbor Laboratory Press, (1988)). Cells are labeled for 8 hours with ³⁵S-cysteine two days post transfection. Culture media are then collected and cells are lysed with detergent (RIPA buffer (150 mM NaCl, 1% NP-40, 0.1% SDS, 1% NP-40, 0.5% DOC, 50 mM Tris, pH 7.5) (Wilson, I. et al., Id. 37:767 (1984)). Both cell lysate and culture media are precipitated with a HA specific monoclonal antibody. Proteins precipitated are analyzed on 15% SDS-PAGE gels.

EXAMPLE 4 Expression via Gene Therapy

[0129] Fibroblasts are obtained from a subject by skin biopsy. The resulting tissue is placed in tissue-culture medium and separated into small pieces. Small chunks of the tissue are placed on a wet surface of a tissue culture flask, approximately ten pieces are placed in each flask. The flask is turned upside down, closed tight and left at room temperature over night. After 24 hours at room temperature, the flask is inverted and the chunks of tissue remain fixed to the bottom of the flask and fresh media (e.g., Ham's F12 media, with 10% FBS, penicillin and streptomycin, is added. This is then incubated at 37° C. for approximately one week. At this time, fresh media is added and subsequently changed every several days. After an additional two weeks in culture, a monolayer of fibroblasts emerge. The monolayer is trypsinized and scaled into larger flasks.

[0130] pMV-7 (Kirschmeier, P. T. et al, DNA, 7:219-25 (1988) flanked by the long terminal repeats of the Moloney murine sarcoma virus, is digested with EcoRI and HindIII and subsequently treated with calf intestinal phosphatase. The linear vector is fractionated on agarose gel and purified, using glass beads.

[0131] The cDNA encoding a polypeptide of the present invention is amplified using PCR primers which correspond to the 5′ and 3′ end sequences respectively. The 5′ primer containing an EcoRI site and the 3′ primer further includes a HindIII site. Equal quantities of the Moloney murine sarcoma virus linear backbone and the amplified EcoRI and HindIII fragment are added together, in the presence of T4 DNA ligase. The resulting mixture is maintained under conditions appropriate for ligation of the two fragments. The ligation mixture is used to transform bacteria HB101, which are then plated onto agar-containing kanamycin for the purpose of confirming that the vector had the gene of interest properly inserted.

[0132] The amphotropic pA317 or GP+am12 packaging cells are grown in tissue culture to confluent density in Dulbecco's Modified Eagles Medium (DMEM) with 10% calf serum (CS), penicillin and streptomycin. The MSV vector containing the gene is then added to the media and the packaging cells are transduced with the vector. The packaging cells now produce infectious viral particles containing the gene (the packaging cells are now referred to as producer cells).

[0133] Fresh media is added to the transduced producer cells, and subsequently, the media is harvested from a 10 cm plate of confluent producer cells. The spent media, containing the infectious viral particles, is filtered through a millipore filter to remove detached producer cells and this media is then used to infect fibroblast cells. Media is removed from a sub-confluent plate of fibroblasts and quickly replaced with the media from the producer cells. This media is removed and replaced with fresh media. If the titer of virus is high, then virtually all fibroblasts will be infected and no selection is required. If the titer is very low, then it is necessary to use a retroviral vector that has a selectable marker, such as neo or his.

[0134] The engineered fibroblasts are then injected into the host, either alone or after having been grown to confluence on cytodex 3 microcarrier beads. The fibroblasts now produce the protein product.

[0135] Numerous modifications and variations of the present invention are possible in light of the above teachings and, therefore, within the scope of the appended claims, the invention may be practiced otherwise than as particularly described.

1 8 1 2034 DNA Homo sapiens CDS (1)..(2034) 1 atg aag gct tcc agc cgc ttc aag gca cac cag gat gca ctg cca cgg 48 Met Lys Ala Ser Ser Arg Phe Lys Ala His Gln Asp Ala Leu Pro Arg 1 5 10 15 ttg ccc gtg ccc cct ctc cag cag tcc ctg gac cac tac ctg aag gcg 96 Leu Pro Val Pro Pro Leu Gln Gln Ser Leu Asp His Tyr Leu Lys Ala 20 25 30 ctg cag ccc atc gtg agt gag gag gag tgg gcc cac acc aag cag ctg 144 Leu Gln Pro Ile Val Ser Glu Glu Glu Trp Ala His Thr Lys Gln Leu 35 40 45 gtg gat gag ttt cag gcc tca gga ggt gta ggg gag cgc ctg cag aag 192 Val Asp Glu Phe Gln Ala Ser Gly Gly Val Gly Glu Arg Leu Gln Lys 50 55 60 ggg ctg gag cgt cgg gcc agg aag acg gag aac tgg ctg tct gag tgg 240 Gly Leu Glu Arg Arg Ala Arg Lys Thr Glu Asn Trp Leu Ser Glu Trp 65 70 75 80 tgg ctc aag acc gcc tac ctc cag tac cgc cag cct gtg gtc atc tac 288 Trp Leu Lys Thr Ala Tyr Leu Gln Tyr Arg Gln Pro Val Val Ile Tyr 85 90 95 tcg agc cca ggc gtg atg cta ccc aag cag gac ttc gtg gac ctg cag 336 Ser Ser Pro Gly Val Met Leu Pro Lys Gln Asp Phe Val Asp Leu Gln 100 105 110 ggt cag ctc cga ttt gct gcc aaa ctc att gag ggt gtg ttg gtt ttc 384 Gly Gln Leu Arg Phe Ala Ala Lys Leu Ile Glu Gly Val Leu Val Phe 115 120 125 aag gtc atg att gac aac gag acc ctg ccc gtg gag tac ctg ggg ggg 432 Lys Val Met Ile Asp Asn Glu Thr Leu Pro Val Glu Tyr Leu Gly Gly 130 135 140 aag cca ctg tgc atg aac cag ttc tat cag atc ttg tcc tcc tgc cga 480 Lys Pro Leu Cys Met Asn Gln Phe Tyr Gln Ile Leu Ser Ser Cys Arg 145 150 155 160 gtg ccg ggc ccc aag cag gac aca gtc agc aac ttc agc aag acc aag 528 Val Pro Gly Pro Lys Gln Asp Thr Val Ser Asn Phe Ser Lys Thr Lys 165 170 175 aag cct ccc acg cac atc acc gtg gta cac aac tac cag ttt ttt gag 576 Lys Pro Pro Thr His Ile Thr Val Val His Asn Tyr Gln Phe Phe Glu 180 185 190 ctg gat gtg tac cac agt gac ggg aca ccc ctc act gcg gat cag atc 624 Leu Asp Val Tyr His Ser Asp Gly Thr Pro Leu Thr Ala Asp Gln Ile 195 200 205 ttt gtg cag ctg gag aag atc tgg aac tca tcc cta cag acc aac aag 672 Phe Val Gln Leu Glu Lys Ile Trp Asn Ser Ser Leu Gln Thr Asn Lys 210 215 220 gag cct gtg ggc atc ctc acc tcc aac cac cgc aac tcc tgg gcc aag 720 Glu Pro Val Gly Ile Leu Thr Ser Asn His Arg Asn Ser Trp Ala Lys 225 230 235 240 gca tac aac acc ctc atc aaa gac aag gtg aac cgg gat tcc gtg cgc 768 Ala Tyr Asn Thr Leu Ile Lys Asp Lys Val Asn Arg Asp Ser Val Arg 245 250 255 tcc atc cag aag agc atc ttc acc gtg tgc cta gat gca acc atg ccc 816 Ser Ile Gln Lys Ser Ile Phe Thr Val Cys Leu Asp Ala Thr Met Pro 260 265 270 agg gtc tca gaa gac gtg tac cgc agc cac gtg gca ggc cag atg ctg 864 Arg Val Ser Glu Asp Val Tyr Arg Ser His Val Ala Gly Gln Met Leu 275 280 285 cat ggg ggc ggc agc agg ctc aac agc ggc aac cgc tgg ttc gac aag 912 His Gly Gly Gly Ser Arg Leu Asn Ser Gly Asn Arg Trp Phe Asp Lys 290 295 300 acg ctg cag ttc atc gtg gca gaa gat ggc tcc tgt ggg ctt gtg tac 960 Thr Leu Gln Phe Ile Val Ala Glu Asp Gly Ser Cys Gly Leu Val Tyr 305 310 315 320 gag cat gct gca gcg gag ggg ccc cct att gtc acc ctt ctg gac tat 1008 Glu His Ala Ala Ala Glu Gly Pro Pro Ile Val Thr Leu Leu Asp Tyr 325 330 335 gtc atc gag tac acg aag aaa ccc gag ctt gtg cgg tct ccc atg gtg 1056 Val Ile Glu Tyr Thr Lys Lys Pro Glu Leu Val Arg Ser Pro Met Val 340 345 350 ccc ctg ccc atg ccc aag aag ctg cgg ttc aac atc acc ccc gag atc 1104 Pro Leu Pro Met Pro Lys Lys Leu Arg Phe Asn Ile Thr Pro Glu Ile 355 360 365 aag agc gac atc gag aag gcc aag cag aac ctc agc atc atg atc cag 1152 Lys Ser Asp Ile Glu Lys Ala Lys Gln Asn Leu Ser Ile Met Ile Gln 370 375 380 gac ctg gat atc acc gtg atg gtg ttc cac cat ttt gga aaa gac ttc 1200 Asp Leu Asp Ile Thr Val Met Val Phe His His Phe Gly Lys Asp Phe 385 390 395 400 ccc aag tcg gag aag cta agc cca gat gcc ttc atc cag atg gct ttg 1248 Pro Lys Ser Glu Lys Leu Ser Pro Asp Ala Phe Ile Gln Met Ala Leu 405 410 415 cag ctg gcc tac tac agg ttc tac gga aag gaa tgt gcc acc tat gaa 1296 Gln Leu Ala Tyr Tyr Arg Phe Tyr Gly Lys Glu Cys Ala Thr Tyr Glu 420 425 430 agt gcc tcc ctg cgc atg ttt cac ctg ggg cgc acc gac acc atc cgc 1344 Ser Ala Ser Leu Arg Met Phe His Leu Gly Arg Thr Asp Thr Ile Arg 435 440 445 tcg ggt tcc atg gac tca ctc acc ttt gtc aag gcc atg gat gac tcc 1392 Ser Gly Ser Met Asp Ser Leu Thr Phe Val Lys Ala Met Asp Asp Ser 450 455 460 agc gtc acg gag cac cag aag gtg gag ctg ctg cgg aag gcc gtg cag 1440 Ser Val Thr Glu His Gln Lys Val Glu Leu Leu Arg Lys Ala Val Gln 465 470 475 480 gcc cac cga ggt tac acc gac cgg gcc atc cgg ggg gag ggc ttt gat 1488 Ala His Arg Gly Tyr Thr Asp Arg Ala Ile Arg Gly Glu Gly Phe Asp 485 490 495 cga cac ctg ctg ggc ctg aag ctg cag gcc atc gag gac ctg gtg agc 1536 Arg His Leu Leu Gly Leu Lys Leu Gln Ala Ile Glu Asp Leu Val Ser 500 505 510 atg ccc gac atc ttc atg gac acc tcc tac gcc atc ggc atg tac ttc 1584 Met Pro Asp Ile Phe Met Asp Thr Ser Tyr Ala Ile Gly Met Tyr Phe 515 520 525 cac ctc tcc acc agg cag gtc cct gcc aag aag atg tgt cat gtt ctt 1632 His Leu Ser Thr Arg Gln Val Pro Ala Lys Lys Met Cys His Val Leu 530 535 540 cgg gcc cgt ggt ccc cga cgg gta cgg tgt ctt tat aac ccc atg gag 1680 Arg Ala Arg Gly Pro Arg Arg Val Arg Cys Leu Tyr Asn Pro Met Glu 545 550 555 560 ggc cac atc aac ttc tcc ctg tcg gac tac aaa agg tgg ggg gag acc 1728 Gly His Ile Asn Phe Ser Leu Ser Asp Tyr Lys Arg Trp Gly Glu Thr 565 570 575 aac gcc gcc cgc ctg gtg tat tac ctg gag aag gcg ctc ctg gac atg 1776 Asn Ala Ala Arg Leu Val Tyr Tyr Leu Glu Lys Ala Leu Leu Asp Met 580 585 590 cgt gcc ctg gtg aag agc cac ccc cgg gcc aag ttc tta gcc cct agg 1824 Arg Ala Leu Val Lys Ser His Pro Arg Ala Lys Phe Leu Ala Pro Arg 595 600 605 act cag gcc tgc caa tgc cac agg caa gcc cac cct agg atg ggc cac 1872 Thr Gln Ala Cys Gln Cys His Arg Gln Ala His Pro Arg Met Gly His 610 615 620 cca cca ggg atc agc tcc ttg gtt ccc tct tcc ttg gtt ccc tct tcc 1920 Pro Pro Gly Ile Ser Ser Leu Val Pro Ser Ser Leu Val Pro Ser Ser 625 630 635 640 ctg gtc ccc cca att cta ctg agc cac gga ccg cat cct cca ggg ggc 1968 Leu Val Pro Pro Ile Leu Leu Ser His Gly Pro His Pro Pro Gly Gly 645 650 655 tgc agg ccc agc caa gtg cct tcc gtg ggt cat ccc agc acc tgc cag 2016 Cys Arg Pro Ser Gln Val Pro Ser Val Gly His Pro Ser Thr Cys Gln 660 665 670 ggc ccg acc tgg ggc tga 2034 Gly Pro Thr Trp Gly 675 2 677 PRT Homo sapiens 2 Met Lys Ala Ser Ser Arg Phe Lys Ala His Gln Asp Ala Leu Pro Arg 1 5 10 15 Leu Pro Val Pro Pro Leu Gln Gln Ser Leu Asp His Tyr Leu Lys Ala 20 25 30 Leu Gln Pro Ile Val Ser Glu Glu Glu Trp Ala His Thr Lys Gln Leu 35 40 45 Val Asp Glu Phe Gln Ala Ser Gly Gly Val Gly Glu Arg Leu Gln Lys 50 55 60 Gly Leu Glu Arg Arg Ala Arg Lys Thr Glu Asn Trp Leu Ser Glu Trp 65 70 75 80 Trp Leu Lys Thr Ala Tyr Leu Gln Tyr Arg Gln Pro Val Val Ile Tyr 85 90 95 Ser Ser Pro Gly Val Met Leu Pro Lys Gln Asp Phe Val Asp Leu Gln 100 105 110 Gly Gln Leu Arg Phe Ala Ala Lys Leu Ile Glu Gly Val Leu Val Phe 115 120 125 Lys Val Met Ile Asp Asn Glu Thr Leu Pro Val Glu Tyr Leu Gly Gly 130 135 140 Lys Pro Leu Cys Met Asn Gln Phe Tyr Gln Ile Leu Ser Ser Cys Arg 145 150 155 160 Val Pro Gly Pro Lys Gln Asp Thr Val Ser Asn Phe Ser Lys Thr Lys 165 170 175 Lys Pro Pro Thr His Ile Thr Val Val His Asn Tyr Gln Phe Phe Glu 180 185 190 Leu Asp Val Tyr His Ser Asp Gly Thr Pro Leu Thr Ala Asp Gln Ile 195 200 205 Phe Val Gln Leu Glu Lys Ile Trp Asn Ser Ser Leu Gln Thr Asn Lys 210 215 220 Glu Pro Val Gly Ile Leu Thr Ser Asn His Arg Asn Ser Trp Ala Lys 225 230 235 240 Ala Tyr Asn Thr Leu Ile Lys Asp Lys Val Asn Arg Asp Ser Val Arg 245 250 255 Ser Ile Gln Lys Ser Ile Phe Thr Val Cys Leu Asp Ala Thr Met Pro 260 265 270 Arg Val Ser Glu Asp Val Tyr Arg Ser His Val Ala Gly Gln Met Leu 275 280 285 His Gly Gly Gly Ser Arg Leu Asn Ser Gly Asn Arg Trp Phe Asp Lys 290 295 300 Thr Leu Gln Phe Ile Val Ala Glu Asp Gly Ser Cys Gly Leu Val Tyr 305 310 315 320 Glu His Ala Ala Ala Glu Gly Pro Pro Ile Val Thr Leu Leu Asp Tyr 325 330 335 Val Ile Glu Tyr Thr Lys Lys Pro Glu Leu Val Arg Ser Pro Met Val 340 345 350 Pro Leu Pro Met Pro Lys Lys Leu Arg Phe Asn Ile Thr Pro Glu Ile 355 360 365 Lys Ser Asp Ile Glu Lys Ala Lys Gln Asn Leu Ser Ile Met Ile Gln 370 375 380 Asp Leu Asp Ile Thr Val Met Val Phe His His Phe Gly Lys Asp Phe 385 390 395 400 Pro Lys Ser Glu Lys Leu Ser Pro Asp Ala Phe Ile Gln Met Ala Leu 405 410 415 Gln Leu Ala Tyr Tyr Arg Phe Tyr Gly Lys Glu Cys Ala Thr Tyr Glu 420 425 430 Ser Ala Ser Leu Arg Met Phe His Leu Gly Arg Thr Asp Thr Ile Arg 435 440 445 Ser Gly Ser Met Asp Ser Leu Thr Phe Val Lys Ala Met Asp Asp Ser 450 455 460 Ser Val Thr Glu His Gln Lys Val Glu Leu Leu Arg Lys Ala Val Gln 465 470 475 480 Ala His Arg Gly Tyr Thr Asp Arg Ala Ile Arg Gly Glu Gly Phe Asp 485 490 495 Arg His Leu Leu Gly Leu Lys Leu Gln Ala Ile Glu Asp Leu Val Ser 500 505 510 Met Pro Asp Ile Phe Met Asp Thr Ser Tyr Ala Ile Gly Met Tyr Phe 515 520 525 His Leu Ser Thr Arg Gln Val Pro Ala Lys Lys Met Cys His Val Leu 530 535 540 Arg Ala Arg Gly Pro Arg Arg Val Arg Cys Leu Tyr Asn Pro Met Glu 545 550 555 560 Gly His Ile Asn Phe Ser Leu Ser Asp Tyr Lys Arg Trp Gly Glu Thr 565 570 575 Asn Ala Ala Arg Leu Val Tyr Tyr Leu Glu Lys Ala Leu Leu Asp Met 580 585 590 Arg Ala Leu Val Lys Ser His Pro Arg Ala Lys Phe Leu Ala Pro Arg 595 600 605 Thr Gln Ala Cys Gln Cys His Arg Gln Ala His Pro Arg Met Gly His 610 615 620 Pro Pro Gly Ile Ser Ser Leu Val Pro Ser Ser Leu Val Pro Ser Ser 625 630 635 640 Leu Val Pro Pro Ile Leu Leu Ser His Gly Pro His Pro Pro Gly Gly 645 650 655 Cys Arg Pro Ser Gln Val Pro Ser Val Gly His Pro Ser Thr Cys Gln 660 665 670 Gly Pro Thr Trp Gly 675 3 34 DNA Artificial sequence Contains a BamHI restriction enzyme site 3 cgcgagatcc accatgaagg cttccagccg cttc 34 4 28 DNA Artificial sequence Contains complementary sequences to an XbaI site 4 cgcgtctaga agggtacaga tggtggcc 28 5 34 DNA Artificial sequence Contains a Bam H1 restriction enzyme site 5 cgcgggatcc accatgaagg cttccagccg cttc 34 6 27 DNA Artificial sequence Contains the cleavage site for the restriction endonuclease As p718 6 cgcgggtacc aggtacagat ggtggcc 27 7 34 DNA Artificial sequence Contains a Bam HI site 7 cgcgggatcc accatgaagg cttccagccg cttc 34 8 58 DNA Artificial sequence Contains complementary sequences to an Xba I site, translation stop codon, and an HA tag 8 cgcgtctaga tcaagcgtag tctgggacgt cgtatgggta gcctctgcac tcagcccc 58 

What is claimed is:
 1. A method of treating a patient, comprising administering to said patient a protein comprising an amino acid sequence selected from the group consisting of: (a) amino acid residues 1 to 677 of SEQ ID NO: 2; (b) amino acid residues 2 to 677 of SEQ ID NO: 2; (c) amino acid residues 1 to 677 of SEQ ID NO: 2, wherein the protein has at least one conservative substitutions, and has choline acetyltransferase activity; (d) an amino acid sequence comprising a fragment of amino acid residues 1 to 677 of SEQ ID NO: 2; wherein the fragment has choline acetyltransferase activity; (e) a polypeptide which is at least 90% identical to the polypeptide of (a)-(d); (f) a polypeptide comprising at least 30 contiguous residues of SEQ ID NO: 2; and (g) a polypeptide comprising at least 50 contiguous residues of SEQ ID NO:
 2. 2. The method of claim 1 wherein said patient suffers from a disorder involving the cholinergic system.
 3. The method of claim 2, wherein the patient suffers from a nervous system disorder.
 4. The method of claim 3, wherein said nervous system disorder is selected from the group consisting of: amyotrophic lateral sclerosis, Alzheimer disease, Parkinson's Disease, senile dementia, multi-infarct dementia, familial disautonomia, Huntington's Disease, mental retardation, memory loss, and myasthenia gravis.
 5. The method of claim 2, wherein said disorder is selected from the group consisting of: gut and GI disorders, cord disorders, including movement, continence and sensation, stem disorders, including sleep, blood pressure, respiration, and balance, hypothalamus disorders, including temperature, respiration, and endocrine function, and limbic system disorders, including schizophrenia, memory disorders, and dementia.
 6. The method of claim 1, wherein said protein comprises (a).
 7. The method of claim 1, wherein said protein comprises (b).
 8. The method of claim 1, wherein said protein comprises (c).
 9. The method of claim 1, wherein said protein comprises (d).
 10. The method of claim 1, wherein said protein comprises (e).
 11. The method of claim 1, wherein said protein comprises (f).
 12. The method of claim 1, wherein said protein comprises (g).
 13. A method of treating a patient, comprising administering to said patient a protein comprising an amino acid sequence selected from the group consisting of: (a) an amino acid sequence of the full-length polypeptide encoded by the cDNA in ATCC Deposit No. 75856; (b) an amino acid sequence of the full-length polypeptide, excluding the N-terminal methionine residue, encoded by the cDNA in ATCC Deposit No. 75856; (c) an amino acid sequence of the full-length polypeptide encoded by the cDNA in ATCC Deposit No. 75856, wherein the amino acid sequence has at least one conservative substitution, and has choline acetyltransferase activity; (d) a fragment of the full-length polypeptide encoded by the cDNA in ATCC Deposit No. 75856, wherein the fragment has choline acetyltransferase activity; (e) a polypeptide which is at least 90% identical to the polypeptide of (a)-(d); (f) a polypeptide comprising at least 30 contiguous residues of the polypeptide encoded by the cDNA in ATCC Deposit No. 75856; and (g) a polypeptide comprising at least 50 contiguous residues of the polypeptide encoded by the cDNA in ATCC Deposit No.
 75856. 14. The method of claim 13 wherein said patient suffers from a disorder involving the cholinergic system.
 15. The method of claim 14, wherein the patient suffers from a nervous system disorder.
 16. The method of claim 15, wherein said nervous system disorder is selected from the group consisting of: amyotrophic lateral sclerosis, Alzheimer disease, Parkinson's Disease, senile dementia, multi-infarct dementia, familial disautonomia, Huntington's Disease, mental retardation, memory loss, and myasthenia gravis.
 17. The method of claim 14, wherein said disorder is selected from the group consisting of: gut and GI disorders, cord disorders, including movement, continence and sensation, stem disorders, including sleep, blood pressure, respiration, and balance, hypothalamus disorders, including temperature, respiration, and endocrine function, and limbic system disorders, including schizophrenia, memory disorders, and dementia.
 18. The method of claim 13, wherein said protein comprises (a).
 19. The method of claim 13, wherein said protein comprises (b).
 20. The method of claim 13, wherein said protein comprises (c).
 21. The method of claim 13, wherein said protein comprises (d).
 22. The method of claim 13, wherein said protein comprises (e).
 23. The method of claim 13, wherein said protein comprises (f).
 24. The method of claim 13, wherein said protein comprises (g).
 25. A method for screening a compound for choline acetyltransferase agonist or antagonist activity, comprising the steps of: exposing a recombinant host cell expressing a polypeptide of the invention to the compound, and evaluating effect of said compound on the choline acetyl transferase activity to thereby determine if the compound has agonist or antagonist activity, wherein said polypeptide of the invention is selected from the group consisting of: (a) amino acid residues 1 to 677 of SEQ ID NO: 2; (b) amino acid residues 2 to 677 of SEQ ID NO: 2; (c) amino acid residues 1 to 677 of SEQ ID NO: 2, wherein the protein has at least one conservative substitution, and choline acetyltransferase activity; (d) an amino acid sequence comprising a fragment of amino acid residues 1 to 677 of SEQ ID NO: 2; wherein the fragment has choline acetyltransferase activity; (e) a polypeptide which is at least 90% identical to the polypeptide of (a)-(d); (f) a polypeptide comprising at least 30 contiguous residues of SEQ ID NO: 2; and (g) a polypeptide comprising at least 50 contiguous residues of SEQ ID NO:
 2. 26. The method of claim 25, wherein said protein comprises (a).
 27. The method of claim 25, wherein said protein comprises (b).
 28. The method of claim 25, wherein said protein comprises (c).
 29. The method of claim 25, wherein said protein comprises (d).
 30. The method of claim 25, wherein said protein comprises (e).
 31. The method of claim 25, wherein said protein comprises (f).
 32. The method of claim 25, wherein said protein comprises (g).
 33. The method of claim 25 wherein said compound is an agonist.
 34. The method of claim 33 wherein said agonist is selected from the group consisting of: (a) small molecule; (b) peptide; and (c) antibody.
 35. The method of claim 34, wherein said antibody is a monoclonal antibody.
 36. The method of claim 34, wherein said antibody is a polyclonal antibody.
 37. The method of claim 34, wherein said antibody is selected from the group consisting of: (a) chimeric antibody; (b) single chain antibody; (c) humanized antibody; and (d) Fab fragments.
 38. The method of claim 25 wherein said compound is an antagonist.
 39. The method of claim 38 wherein said antagonist is selected from the group consisting of: (a) small molecule; (b) peptide; and (c) antibody.
 40. The method of claim 39, wherein said antibody is a monoclonal antibody.
 41. The method of claim 39, wherein said antibody is a polyclonal antibody.
 42. The method of claim 39, wherein said antibody is selected from the group consisting of: (a) chimeric antibody; (b) single chain antibody; (c) humanized antibody; and (d) Fab fragments.
 43. A method for screening a compound for choline acetyltransferase agonist or antagonist activity, comprising the steps of: exposing a recombinant host cell expressing a polypeptide of the invention to the compound, and evaluating effect of said compound on the choline acetyl transferase activity to thereby determine if the compound has agonist or antagonist activity, wherein said polypeptide of the invention is selected from the group consisting of: (a) an amino acid sequence of the full-length polypeptide encoded by the cDNA in ATCC Deposit No. 75856; (b) an amino acid sequence of the full-length polypeptide, excluding the N-terminal methionine residue, encoded by the cDNA in ATCC Deposit No. 75856; (c) an amino acid sequence of the full-length polypeptide encoded by the cDNA in ATCC Deposit No. 75856, wherein the amino acid sequence has at least one conservative substitution, and has choline acetyltransferase activity; (d) a fragment of the full-length polypeptide encoded by the cDNA in ATCC Deposit No. 75856, wherein the fragment has choline acetyltransferase activity; (e) a polypeptide which is at least 90% identical to the polypeptide of (a)-(d); (f) a polypeptide comprising at least 30 contiguous residues of polypeptide encoded by the cDNA in ATCC Deposit No. 75856; and (g) a polypeptide comprising at least 50 contiguous residues of polypeptide encoded by the cDNA in ATCC Deposit No.
 75856. 44. The method of claim 43, wherein said protein comprises (a).
 45. The method of claim 43, wherein said protein comprises (b).
 46. The method of claim 43, wherein said protein comprises (c).
 47. The method of claim 43, wherein said protein comprises (d).
 48. The method of claim 43, wherein said protein comprises (e).
 49. The method of claim 43, wherein said protein comprises (f).
 50. The method of claim 43, wherein said protein comprises (g).
 51. The method of claim 43 wherein said compound is an agonist.
 52. The method of claim 51 wherein said agonist is selected from the group consisting of: (a) small molecule; (b) peptide; and (c) antibody.
 53. The method of claim 52, wherein said antibody is a monoclonal antibody.
 54. The method of claim 52, wherein said antibody is a polyclonal antibody.
 55. The method of claim 52, wherein said antibody is selected from the group consisting of: (a) chimeric antibody; (b) single chain antibody; (c) humanized antibody; and (d) Fab fragments.
 56. The method of claim 43 wherein said compound is an antagonist.
 57. The method of claim 56 wherein said antagonist is selected from the group consisting of: (a) small molecule; (b) peptide; and (c) antibody.
 58. The method of claim 57, wherein said antibody is a monoclonal antibody.
 59. The method of claim 57, wherein said antibody is a polyclonal antibody.
 60. The method of claim 57, wherein said antibody is selected from the group consisting of: (a) chimeric antibody; (b) single chain antibody; (c) humanized antibody; and (d) Fab fragments.
 61. A method of treating a patient, comprising administering to a patient an agonist of a protein comprising an amino acid sequence selected from the group consisting of: (a) amino acid residues 1 to 677 of SEQ ID NO: 2; (b) amino acid residues 2 to 677 of SEQ ID NO: 2; (c) amino acid residues 1 to 677 of SEQ ID NO: 2, wherein the protein has at least one conservative substitution, and has choline acetyltransferase activity; (d) an amino acid sequence comprising a fragment of amino acid residues 1 to 677 of SEQ ID NO: 2; wherein the fragment has choline acetyltransferase activity; (e) a polypeptide which is at least 90% identical to the polypeptide of (a)-(d); (f) a polypeptide comprising at least 30 contiguous residues of SEQ ID NO: 2; and (g) a polypeptide comprising at least 50 contiguous residues of SEQ ID NO:
 2. 62. The method of claim 61 wherein said patient suffers from a disorder involving the cholinergic system.
 63. The method of claim 62, wherein the patient suffers from a nervous system disorder.
 64. The method of claim 63, wherein said nervous system disorder is selected from the group consisting of: amyotrophic lateral sclerosis, Alzheimer disease, Parkinson's Disease, senile dementia, multi-infarct dementia, familial disautonomia, Huntington's Disease, mental retardation, memory loss, and myasthenia gravis.
 65. The method of claim 62, wherein said disorder is selected from the group consisting of: gut and GI disorders, cord disorders, including movement, continence and sensation, stem disorders, including sleep, blood pressure, respiration, and balance, hypothalamus disorders, including temperature, respiration, and endocrine function, and limbic system disorders, including schizophrenia, memory disorders, and dementia.
 66. The method of claim 61, wherein said protein comprises (a).
 67. The method of claim 61, wherein said protein comprises (b).
 68. The method of claim 61, wherein said protein comprises (c).
 69. The method of claim 61, wherein said protein comprises (d).
 70. The method of claim 61, wherein said protein comprises (e).
 71. The method of claim 61, wherein said protein comprises (f).
 72. The method of claim 61, wherein said protein comprises (g).
 73. The method of claim 61 wherein said agonist is selected from the group consisting of: (d) small molecule; (e) peptide; and (f) antibody.
 74. The method of claim 73, wherein said antibody is a monoclonal antibody.
 75. The method of claim 73, wherein said antibody is a polyclonal antibody.
 76. The method of claim 73, wherein said antibody is selected from the group consisting of: (d) chimeric antibody; (e) single chain antibody; (f) humanized antibody; and (g) Fab fragments.
 77. A method of treating a patient, comprising administering to a patient an agonist of a protein comprising an amino acid sequence selected from the group consisting of: (a) an amino acid sequence of the full-length polypeptide encoded by the cDNA in ATCC Deposit No. 75856; (b) an amino acid sequence of the full-length polypeptide, excluding the N-terminal methionine residue, encoded by the cDNA in ATCC Deposit No. 75856; (c) an amino acid sequence of the full-length polypeptide encoded by the cDNA in ATCC Deposit No. 75856, wherein the amino acid sequence has at least one conservative substitution, and has choline acetyltransferase activity; (d) a fragment of the full-length polypeptide encoded by the cDNA in ATCC Deposit No. 75856, wherein the fragment has choline acetyltransferase activity; (e) a polypeptide which is at least 90% identical to the polypeptide of (a)-(d); (f) a polypeptide comprising at least 30 contiguous residues of polypeptide encoded by the cDNA in ATCC Deposit No. 75856; and (g) a polypeptide comprising at least 50 contiguous residues of polypeptide encoded by the cDNA in ATCC Deposit No.
 75856. 78. The method of claim 77 wherein said patient suffers from a disorder involving the cholinergic system.
 79. The method of claim 78, wherein the patient suffers from a nervous system disorder.
 80. The method of claim 79, wherein said nervous system disorder is selected from the group consisting of: amyotrophic lateral sclerosis, Alzheimer disease, Parkinson's Disease, senile dementia, multi-infarct dementia, familial disautonomia, Huntington's Disease, mental retardation, memory loss, and myasthenia gravis.
 81. The method of claim 78, wherein said disorder is selected from the group consisting of: gut and GI disorders, cord disorders, including movement, continence and sensation, stem disorders, including sleep, blood pressure, respiration, and balance, hypothalamus disorders, including temperature, respiration, and endocrine function, and limbic system disorders, including schizophrenia, memory disorders, and dementia.
 82. The method of claim 77, wherein said protein comprises (a).
 83. The method of claim 77, wherein said protein comprises (b).
 84. The method of claim 77, wherein said protein comprises (c).
 85. The method of claim 77, wherein said protein comprises (d).
 86. The method of claim 77, wherein said protein comprises (e).
 87. The method of claim 77, wherein said protein comprises (f).
 88. The method of claim 77, wherein said protein comprises (g).
 89. The method of claim 77 wherein said agonist is selected from the group consisting of: (a) small molecule; (b) peptide; and (c) antibody.
 90. The method of claim 89, wherein said antibody is a monoclonal antibody.
 91. The method of claim 89, wherein said antibody is a polyclonal antibody.
 92. The method of claim 89, wherein said antibody is selected from the group consisting of: (a) chimeric antibody; (b) single chain antibody; (c) humanized antibody; and (d) Fab fragments.
 93. A method of treating a patient, comprising administering to a patient an antagonist of a protein comprising an amino acid sequence selected from the group consisting of: (a) amino acid residues 1 to 677 of SEQ ID NO: 2; (b) amino acid residues 2 to 677 of SEQ ID NO: 2; (c) amino acid residues 1 to 677 of SEQ ID NO: 2, wherein the protein has at least one conservative substitution, and has choline acetyltransferase activity; (d) an amino acid sequence comprising a fragment of amino acid residues 1 to 677 of SEQ ID NO: 2; wherein the fragment has choline acetyltransferase activity; (e) a polypeptide which is at least 90% identical to the polypeptide of (a)-(d); (f) a polypeptide comprising at least 30 contiguous residues of SEQ ID NO: 2; and (g) a polypeptide comprising at least 50 contiguous residues of SEQ ID NO:
 2. 94. The method of claim 93 wherein said patient suffers from a disorder involving the cholinergic system.
 95. The method of claim 94, wherein the patient suffers from a nervous system disorder.
 96. The method of claim 95, wherein said nervous system disorder is selected from the group consisting of: amyotrophic lateral sclerosis, Alzheimer disease, Parkinson's Disease, senile dementia, multi-infarct dementia, familial disautonomia, Huntington's Disease, mental retardation, memory loss, and myasthenia gravis.
 97. The method of claim 94, wherein said disorder is selected from the group consisting of: gut and GI disorders, cord disorders, including movement, continence and sensation, stem disorders, including sleep, blood pressure, respiration, and balance, hypothalamus disorders, including temperature, respiration, and endocrine function, and limbic system disorders, including schizophrenia, memory disorders, and dementia.
 98. The method of claim 93, wherein said protein comprises (a).
 99. The method of claim 93, wherein said protein comprises (b).
 100. The method of claim 93, wherein said protein comprises (c).
 101. The method of claim 93, wherein said protein comprises (d).
 102. The method of claim 93, wherein said protein comprises (e).
 103. The method of claim 93, wherein said protein comprises (f).
 104. The method of claim 93, wherein said protein comprises (g).
 105. The method of claim 93 wherein said antagonist is selected from the group consisting of: (a) small molecule; (b) peptide; and (c) antibody.
 106. The method of claim 105, wherein said antibody is a monoclonal antibody.
 107. The method of claim 105, wherein said antibody is a polyclonal antibody.
 108. The method of claim 105, wherein said antibody is selected from the group consisting of: (a) chimeric antibody; (b) single chain antibody; (c) humanized antibody; and (d) Fab fragments.
 109. A method of treating a patient, comprising administering to a patient an antagonist of a polypeptide of amino acid sequence selected from the group consisting of: (a) an amino acid sequence of the full-length polypeptide encoded by the cDNA in ATCC Deposit No. 75856; (b) an amino acid sequence of the full-length polypeptide, excluding the N-terminal methionine residue, encoded by the cDNA in ATCC Deposit No. 75856; (c) an amino acid sequence of the full-length polypeptide encoded by the cDNA in ATCC Deposit No. 75856, wherein the amino acid sequence has at least one conservative substitution, and has choline acetyltransferase activity; (d) a fragment of the full-length polypeptide encoded by the cDNA in ATCC Deposit No. 75856, wherein the fragment has choline acetyltransferase activity; (e) a polypeptide which is at least 90% identical to the polypeptide of (a)-(d); (f) a polypeptide comprising at least 30 contiguous residues of polypeptide encoded by the cDNA in ATCC Deposit No. 75856; and (g) a polypeptide comprising at least 50 contiguous residues of polypeptide encoded by the cDNA in ATCC Deposit No.
 75856. 110. The method of claim 109 wherein said patient suffers from a disorder involving the cholinergic system.
 111. The method of claim 110, wherein the patient suffers from a nervous system disorder.
 112. The method of claim 111, wherein said nervous system disorder is selected from the group consisting of: amyotrophic lateral sclerosis, Alzheimer disease, Parkinson's Disease, senile dementia, multi-infarct dementia, familial disautonomia, Huntington's Disease, mental retardation, memory loss, and myasthenia gravis.
 113. The method of claim 110, wherein said disorder is selected from the group consisting of: gut and GI disorders, cord disorders, including movement, continence and sensation, stem disorders, including sleep, blood pressure, respiration, and balance, hypothalamus disorders, including temperature, respiration, and endocrine function, and limbic system disorders, including schizophrenia, memory disorders, and dementia.
 114. The method of claim 109, wherein said protein comprises (a).
 115. The method of claim 109, wherein said protein comprises (b).
 116. The method of claim 109, wherein said protein comprises (c).
 117. The method of claim 109, wherein said protein comprises (d).
 118. The method of claim 109, wherein said protein comprises (e).
 119. The method of claim 109, wherein said protein comprises (f).
 120. The method of claim 109, wherein said protein comprises (g).
 121. The method of claim 109 wherein said antagonist is selected from the group consisting of: (a) small molecule; (b) peptide; and (c) antibody.
 122. The method of claim 121, wherein said antibody is a monoclonal antibody.
 123. The method of claim 121, wherein said antibody is a polyclonal antibody.
 124. The method of claim 121, wherein said antibody is selected from the group consisting of: (a) chimeric antibody; (b) single chain antibody; (c) humanized antibody; and (d) Fab fragments.
 125. A method of diagnosing a disorder in a patient, said method comprising determining, in a sample from said patient, the level of a nucleic acid encoding a polypeptide comprising the amino acid sequence of SEQ ID NO: 2, wherein a level of said nucleic acid in said sample from said patient that differs from the level in a control sample indicates that said patient has a disorder.
 126. The method of claim 125 wherein said disorder involves the cholinergic system.
 127. The method of claim 126, wherein the patient suffers from a nervous system disorder.
 128. The method of claim 127, wherein said nervous system disorder is selected from the group consisting of: amyotrophic lateral sclerosis, Alzheimer disease, Parkinson's Disease, senile dementia, multi-infarct dementia, familial disautonomia, Huntington's Disease, mental retardation, memory loss, and myasthenia gravis.
 129. The method of claim 126, wherein said disorder is selected from the group consisting of: gut and GI disorders, cord disorders, including movement, continence and sensation, stem disorders, including sleep, blood pressure, respiration, and balance, hypothalamus disorders, including temperature, respiration, and endocrine function, and limbic system disorders, including schizophrenia, memory disorders, and dementia.
 130. A method of diagnosing a disorder in a patient, said method comprising determining, in a sample from said patient, the level of a nucleic acid encoding a polypeptide comprising the amino acid sequence of the cDNA contained in Deposit No. 75856, wherein a level of said nucleic acid in said sample from said patient that differs from the level in a control sample indicates that said patient has a disorder.
 131. The method of claim 130 wherein said disorder involves the cholinergic system.
 132. The method of claim 131, wherein the patient suffers from a nervous system disorder.
 133. The method of claim 132, wherein said nervous system disorder is selected from the group consisting of: amyotrophic lateral sclerosis, Alzheimer disease, Parkinson's Disease, senile dementia, multi-infarct dementia, familial disautonomia, Huntington's Disease, mental retardation, memory loss, and myasthenia gravis.
 134. The method of claim 131, wherein said disorder is selected from the group consisting of: gut and GI disorders, cord disorders, including movement, continence and sensation, stem disorders, including sleep, blood pressure, respiration, and balance, hypothalamus disorders, including temperature, respiration, and endocrine function, and limbic system disorders, including schizophrenia, memory disorders, and dementia.
 135. A method of diagnosing a disorder in a patient, said method comprising determining, in a sample from said patient, the level of a polypeptide of amino acid sequence SEQ ID NO: 2, wherein a level of said polypeptide in said sample from said patient that differs from the level in a control sample indicates that said patient has a disorder.
 136. The method of claim 135 wherein said disorder involves the cholinergic system.
 137. The method of claim 136, wherein the patient suffers from a nervous system disorder.
 138. The method of claim 137, wherein said nervous system disorder is selected from the group consisting of: amyotrophic lateral sclerosis, Alzheimer disease, Parkinson's Disease, senile dementia, multi-infarct dementia, familial disautonomia, Huntington's Disease, mental retardation, memory loss, and myasthenia gravis.
 139. The method of claim 136, wherein said disorder is selected from the group consisting of: gut and GI disorders, cord disorders, including movement, continence and sensation, stem disorders, including sleep, blood pressure, respiration, and balance, hypothalamus disorders, including temperature, respiration, and endocrine function, and limbic system disorders, including schizophrenia, memory disorders, and dementia.
 140. A method of diagnosing a disorder in a patient, said method comprising determining, in a sample from said patient, the level of a polypeptide comprising the amino acid sequence of the cDNA contained in Deposit No. 75856, wherein a level of said polypeptide in said sample from said patient that differs from the level in a control sample indicates that said patient has a disorder.
 141. The method of claim 140 wherein said disorder involves the cholinergic system.
 142. The method of claim 141, wherein the patient suffers from a nervous system disorder.
 143. The method of claim 142, wherein said nervous system disorder is selected from the group consisting of: amyotrophic lateral sclerosis, Alzheimer disease, Parkinson's Disease, senile dementia, multi-infarct dementia, familial disautonomia, Huntington's Disease, mental retardation, memory loss, and myasthenia gravis.
 144. The method of claim 141, wherein said disorder is selected from the group consisting of: gut and GI disorders, cord disorders, including movement, continence and sensation, stem disorders, including sleep, blood pressure, respiration, and balance, hypothalamus disorders, including temperature, respiration, and endocrine function, and limbic system disorders, including schizophrenia, memory disorders, and dementia.
 145. A method of treating a patient, comprising administering to said patient a polynucleotide which encodes a protein comprising an amino acid sequence selected from the group consisting of: (a) amino acid residues 1 to 677 of SEQ ID NO: 2; (b) amino acid residues 2 to 677 of SEQ ID NO: 2; (c) amino acid residues 1 to 677 of SEQ ID NO: 2, wherein the protein has at least one conservative substitution, and has choline acetyltransferase activity; (d) an amino acid sequence comprising a fragment of amino acid residues 1 to 677 of SEQ ID NO: 2; wherein the fragment has choline acetyltransferase activity; (e) a polypeptide which is at least 90% identical to the polypeptide of (a)-(d); (f) a polypeptide comprising at least 30 contiguous residues of SEQ ID NO: 2; and (g) a polypeptide comprising at least 50 contiguous residues of SEQ ID NO:
 2. 146. The method of claim 145 wherein said patient suffers from a disorder involving the cholinergic system.
 147. The method of claim 146, wherein the patient suffers from a nervous system disorder.
 148. The method of claim 147, wherein said nervous system disorder is selected from the group consisting of: amyotrophic lateral sclerosis, Alzheimer disease, Parkinson's Disease, senile dementia, multi-infarct dementia, familial disautonomia, Huntington's Disease, mental retardation, memory loss, and myasthenia gravis.
 149. The method of claim 146, wherein said disorder is selected from the group consisting of: gut and GI disorders, cord disorders, including movement, continence and sensation, stem disorders, including sleep, blood pressure, respiration, and balance, hypothalamus disorders, including temperature, respiration, and endocrine function, and limbic system disorders, including schizophrenia, memory disorders, and dementia.
 150. The method of claim 145, wherein said protein comprises (a).
 151. The method of claim 145, wherein said protein comprises (b).
 152. The method of claim 145, wherein said protein comprises (c).
 153. The method of claim 145, wherein said protein comprises (d).
 154. The method of claim 145, wherein said protein comprises (e).
 155. The method of claim 145, wherein said protein comprises (f).
 156. The method of claim 145, wherein said protein comprises (g).
 157. A method of treating a patient, comprising administering to said patient a polynucleotide which encodes a protein comprising an amino acid sequence selected from the group consisting of: (a) an amino acid sequence of the full-length polypeptide encoded by the cDNA in ATCC Deposit No. 75856; (b) an amino acid sequence of the full-length polypeptide, excluding the N-terminal methionine residue, encoded by the cDNA in ATCC Deposit No. 75856; (c) an amino acid sequence of the full-length polypeptide encoded by the cDNA in ATCC Deposit No. 75856, wherein the amino acid sequence has at least one conservative substitution, and has choline acetyltransferase activity; (d) a fragment of the full-length polypeptide encoded by the cDNA in ATCC Deposit No. 75856, wherein the fragment has choline acetyltransferase activity; (e) a polypeptide which is at least 90% identical to the polypeptide of (a)-(d); (f) a polypeptide comprising at least 30 contiguous residues of polypeptide encoded by the cDNA in ATCC Deposit No. 75856; and (g) a polypeptide comprising at least 50 contiguous residues of polypeptide encoded by the cDNA in ATCC Deposit No.
 75856. 158. The method of claim 157 wherein said patient suffers from a disorder involving the cholinergic system.
 159. The method of claim 158, wherein the patient suffers from a nervous system disorder.
 160. The method of claim 159, wherein said nervous system disorder is selected from the group consisting of: amyotrophic lateral sclerosis, Alzheimer disease, Parkinson's Disease, senile dementia, multi-infarct dementia, familial disautonomia, Huntington's Disease, mental retardation, memory loss, and myasthenia gravis.
 161. The method of claim 158, wherein said disorder is selected from the group consisting of: gut and GI disorders, cord disorders, including movement, continence and sensation, stem disorders, including sleep, blood pressure, respiration, and balance, hypothalamus disorders, including temperature, respiration, and endocrine function, and limbic system disorders, including schizophrenia, memory disorders, and dementia.
 162. The method of claim 157, wherein said protein comprises (a).
 163. The method of claim 157, wherein said protein comprises (b).
 164. The method of claim 157, wherein said protein comprises (c).
 165. The method of claim 157, wherein said protein comprises (d).
 166. The method of claim 157, wherein said protein comprises (e).
 167. The method of claim 157, wherein said protein comprises (f).
 168. The method of claim 157, wherein said protein comprises (g). 